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Over the past few years, developments of applications in the CRISPR-Cas9 
system have increased explosively, not only for efficient genome engineering but 
also for recruiting variety range of functional domains at a target locus. In the 
presence of an exogenous DNA template with homologous sequence, point 
mutations can be introduced at Cas9 nuclease-mediated DSBs by homology-
directed repair (HDR), one of endogenous cellular repair mechanism. However, the 
efficiency of HDR is modest since competitive non-homologous end joining 
(NHEJ) pathway is predominant. Also, it has large variations on the cell type.  
Recently developed base-editing systems present a useful orthogonal strategy 
for manipulating nucleotide substitutions. CRISPR RNA-guided base editors, 
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fusion proteins consist of a catalytically defective Sterptococcus pyogenes Cas9 
and deaminases, convert single-nucleotide in the target DNA. Base editing systems 
are divided into two categories: cytosine base editors (CBEs) that convert C to T 
and adenosine base editors (ABEs) that convert A to G. Unlike programmable 
nucleases which produce small indels at a target site, base editing systems have the 
advantage that can induce base conversions, not relying on the DSB repair pathway. 
Despite broad interest in base editing, genome-wide target specificities of CRISPR 
RNA-guided base editors remain unknown. Several methods for off-target 
detection are established; however, existing methods are based on capturing of 
DSBs, and they are not suitable for programmable deaminases.  
In this thesis, I will describe a new method for assessing genome-wide 
specificities of CRISPR RNA-guided base editing by modifying Digenome-seq. I 
validate off-targets of CBEs and confirm that CBEs are highly specific compared 
to CRISPR nucleases. To reduce the off-target effects, I use modified sgRNAs and 
observe that both extended and truncated sgRNAs improve the specificities of 
CRISPR RNA-guided base editors. Furthermore, extended sgRNAs show base 
editing in additional nucleotides at positions out of canonical base editing windows, 
demonstrating the expansion of targeting-scope of CRISPR RNA-guided 
deaminases. 
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Programmable nucleases mediated genome engineering has been widely 
used to understand the function of a gene or a specific mutation in sequence (Kim 
and Kim, 2014). Programmable nucleases, such as zinc finger nucleases (ZFNs) 
(Bibikova et al., 2003; Doyon et al., 2008; Maeder et al., 2008; Urnov et al., 2005), 
transcriptional activator-like effector nucleases (TALENs) (Boch et al., 2009; 
Cermak et al., 2011; Kim et al., 2013; Miller et al., 2011; Moscou and Bogdanove, 
2009) and clustered regularly interspaced short palindromic repeat (CRISPR) 
nucleases (Cho et al., 2013; Cong et al., 2013; Hwang et al., 2013; Jiang et al., 
2013; Jinek et al., 2012; Mali et al., 2013b), create double-strand breaks (DSBs) at 
a specific locus in the genome. Two major pathways for repair of cellular DSBs are 
non-homologous end joining (NHEJ) and homologous recombination (HR) 
(Chapman et al., 2012; Liang et al., 1998). The predominant NHEJ pathway is an 
error-prone process that eliminates DSBs by direct ligation (Shrivastav et al., 2008) 
and mostly generates small insertions or deletions (indels) leading to frameshift 
mutations. In the presence of a homologous DNA template, DSB sites can be 
replaced through the HR using homologous DNA sequence leading to gene 
correction or gene insertion.  
ZFNs and TALENs have a common feature that they are recombinant 
proteins made by artificially linking a sequence-specific DNA-binding protein, like 
zinc finger protein (ZFP) or TAL effector (TALE), with a protein having a cleaving 
activity, like nuclease domain of Fok1 restriction enzyme. Each ZFP recognizes 
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nucleotide triplets, and a combination of 3-6 zinc fingers provides target specific 
binding in 9-18 base pairs (Bitinaite et al., 1998; Urnov et al., 2005). TALEs, 
derived from the plant pathogenic bacteria such as Xanthomonas spp., contain 
repeat variable di-residues (RVDs) which determine the recognition of a single 
base pair (Boch et al., 2009; Moscou and Bogdanove, 2009). Target specific 
TALEs are made by a combination of 15-20 modules with containing engineered 
RVDs. Both ZFNs and TALENs identify the target DNA by protein-DNA 
interactions, so ZFP and TALE must be changed each time to match with their 
target sequence. For DNA cleavage by nuclease domain of Fok1 in ZFNs and 
TALENs, a pair of ZFNs or TALENs are required since Fok1 domain functions as 
a dimer (Bitinaite et al., 1998).  
Unlike ZFNs and TALENs, CRISPR nucleases have different composition 
and mechanism. CRISPR system as a genome engineering tool is developed based 
on CRISPR immune system, the adaptive immune system in eubacteria and 
archaea (Garneau et al., 2010; Marraffini and Sontheimer, 2010). 
CRISPR/CRISPR-associated (Cas) immune system is divided into three stages :1) 
Acquisition of small foreign DNA (protospacers) from invaders in to CRISPR 
array; 2) Expression of Cas genes and transcribing trans-activating crRNA 
(tracrRNA) and pre-CRISPR RNA (pre-crRNA) which becomes crRNA after 
processing; 3) Interference of reinvading DNA, by target recognition and 
degradation of CRISPR components (Marraffini, 2015). CRISPR systems are 
classified into class 1 and class 2 (Makarova et al., 2017a, b), depending on 
whether it has single effector protein or multi-complexes. Class 2 system utilizes a 
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processed crRNA and single effector protein such as Cas9 from Streptococcus 
pyogenes, the most efficient and widely used for genome engineering in various 
organisms (Kim and Kim, 2014; Shmakov et al., 2017).  
To cut double-stranded DNA, it requires crRNA, tracrRNA, and Cas9 
protein. The crRNA is made from DNA obtained from a spacer acquisition and 
binds to the target DNA. The tracrRNA is complementary to some sequence of 
crRNA and serves to make Cas9 cleave DNA. The Cas9 protein generates DSB 
when the protospacer adjacent motif (PAM) is present after the crRNA binding 
region. For more convenient use, crRNA and tracrRNA are fused into one strand, 
which is called single-guide RNA (sgRNA), through the identification of essential 
sequence in working. By changing the sequence of crRNA or sgRNA, 20 
nucleotides (nt) target sequence that hybridizes to the complementary sequence on 
the genome, it can easily change the cutting sites, and it has been confirmed in vitro 
and in vivo. Now, it is used as an easy-to-use technique, not only for knock-out 
research to eliminate the function of genes, but also the production of the disease 
model, correction of genetic disease, and improvement of animals and plants. 
Modification of Cas9 protein or sgRNA, two major components of the 
CRISPR-Cas9 nucleases, can be used for further applications (Adli, 2018). Cas9 
has two different cleavage domains, RuvC and HNH, which cleave non-target 
strand and target strand of DNA, respectively. Mutations in the catalytic residues of 
Cas9 nuclease (D10A in RuvC, H840A in HNH, or both) convert into catalytically-
impaired Cas9 nickase (nCas9) or catalytically-deficient Cas9 (dCas9). nCas9 and 
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dCas9 still retain the property of specifically binding to the target DNA (Jinek et al., 
2012), so it can be fused with various functional protein domains to induce new 
functions at specific genome locus. For example, CRISPR activation (CRISPRa) 
and CRISPR interference (CRISPRi) systems regulate the gene expression by fused 
domain of transcription activator, four herpes simplex virus VP16 molecules 
(called VP64), or transcription repressor, the Krüppel-associated box (KRAB) with 
dCas9 (Gilbert et al., 2014; Konermann et al., 2015; Maeder et al., 2013; Perez-
Pinera et al., 2013). Also, additional RNA motif in sgRNA, linked at positions that 
do not affect the formation of the complex with Cas9, recruits other functional 
domains (Ma et al., 2018; Zalatan et al., 2015).  
For therapeutic use, it is crucial to target the point mutations, a major 
source of human genetic disorders (Rees and Liu, 2018) and diversity. Introducing 
substitutions in the target locus is necessary for correction of disease or studying 
the function of specific nucleotides. Using CRISPR nucleases and a donor DNA 
template with point mutations, it is now possible to induce point mutations at the 
desired site. However, the efficiency of HR-induced point mutations is much lower 
than competitive NHEJ pathway, so there have been attempts to increase efficiency. 
Through NHEJ inhibitor or cell cycle regulation, HR efficiency is slightly 
increased, but it is not sufficient compared to the frequency of indels with NHEJ 
(Chu et al., 2015; Maruyama et al., 2015). 
CRISPR RNA-guided programmable deaminases, composed of a nCas9 
or dCas9 from S. pyogenes and a deaminase protein from various sources, enable 
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targeted nucleotide substitutions or base editing in a genome without producing 
DSBs. These base editing systems can be divided into two categories: cytosine base 
editors (CBEs) that convert a C:G base pair to a T:A pair (Hess et al., 2016; Komor 
et al., 2016; Ma et al., 2016; Nishida et al., 2016; Yang et al., 2016) and adenosine 
base editors (ABEs) that convert a A:T pair to a G:C pair (Gaudelli et al., 2017). 
Unlike programmable nucleases which induce small indels at a target site, 
programmable deaminases convert bases within a window of several nucleotides at 
a target site without relying on endogenous DSB repair pathways. nCas9 or dCas9 
binds to target DNA and generates single-stranded DNA bubble by forming R-loop 
complex (Jiang et al., 2016). Then, linked single-strand-specific deaminase convert 
the exposed cytosine or adenine to uracil (U) or inosine (I) on the non-target strand. 
By DNA repair systems and replication process, U:G or I:T mismatches are 
resolved to produce U:A or I:C and lastly, T:A or G:C base pairs. Through these 
mechanisms, programmable deaminases can correct point mutations causing 
genetic diseases or create single-nucleotide polymorphisms (SNPs) of interest in 
human cells (Gaudelli et al., 2017; Kim et al., 2017a; Komor et al., 2016), animals 
(Kim et al., 2017b; Ryu et al., 2018), and plants (Kang et al., 2018; Zong et al., 
2017). 
Target specificity of CRISPR nucleases is determined by the sequence of 
sgRNA. The sgRNA binds to its complementary target DNA and specifies the 
position to cut. But there are hundreds of homologous sites that differ from the on-
target sequence by up to 5-nt mismatches in the human genome; indeed, unwanted 
mutations caused by off-target effects of CRISPR nucleases have been reported 
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(Cho et al., 2014; Fu et al., 2013; Hsu et al., 2013; Kosicki et al., 2018). It is 
important to develop a method to identify the off-targets across the genome and to 
reduce them. Several methods for off-target detection are established using 
computational prediction tool (Bae et al., 2014; Heigwer et al., 2014; Ran et al., 
2013b), capturing bound target with Cas9 (Duan et al., 2014; Kuscu et al., 2014; 
Singh et al., 2015; Wu et al., 2014), or capturing the consequences of DSBs (Frock 
et al., 2015; Kim et al., 2015; Tsai et al., 2017; Tsai et al., 2015; Wang et al., 2015) 
in vitro and in vivo. Also, various strategies have been reported to reduce off-target 
effects of Cas9 nucleases: alteration the length of sgRNA including shortening (Fu 
et al., 2014) or adding guanine at 5’ end (Cho et al., 2014), weakening the non-
specific interaction between Cas9 protein and non-target (Slaymaker et al., 2016) 
or target strand (Kleinstiver et al., 2016) of DNA, using as paired Cas9 nickases 
(Cho et al., 2014; Mali et al., 2013a; Ran et al., 2013a) or dCas9-FokI (Guilinger et 
al., 2014; Tsai et al., 2014), and delivery as ribonucleoprotein (Kim et al., 2014; 
Ramakrishna et al., 2014; Zuris et al., 2015). However, genome-wide target 
specificities of programmable deaminases remain unknown, owing to a lack of 
appropriate methods. Existing methods for identifying genome-wide off-targets are 
based on capturing of DSBs introduced by CRISPR nucleases, and it is not suitable 
for programmable deaminases.  
Here, I modify Digenome-seq to assess the genome-wide specificities of 
CRISPR RNA-guided programmable deaminases. I identify off-targets of CBEs 
and confirm that CBEs are highly specific compared to CRISPR nucleases. By 
using modified sgRNAs, I find that both extended and truncated sgRNAs reduce 
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the off-target effects at identified off-target sites (Kim et al., 2017a). Furthermore, 
extended sgRNAs show base editing in additional nucleotides at the 5’ end, 
demonstrating that the targeting-scope of CRISPR RNA-guided deaminases have 





Ⅱ. Materials and Methods 
 
1. Cell culture and transfection conditions 
HEK293T cells (ATCC CRL-11268) and NIH3T3 cells (ATCC CRL-1658) 
were maintained in DMEM medium supplemented with 10% fetal bovine serum 
(FBS) and 1% penicillin/streptomycin (Welgene) and verified using STR profile. 
Cells were not tested for mycoplasma contamination. 
For CBE experiments, HEK293T cells (~ 1.5 × 105) were seeded on 24-
well plates and transfected at ~80% confluency with Base Editor-expression 
plasmid (Addgene plasmid #73019, #73020, #73021) (1.5 μg) or Cas9-expression 
plasmid (Addgene plasmid #43945) and sgRNA-expressing plasmid (500 ng) using 
Lipofectamine 2000 (Thermo Fisher Scientific). NIH3T3 cells (1 × 105) were 
electroporated with Base Editor-expression plasmid (1.3 μg) and sgRNA plasmid 
(1.3 μg) via Neon Transfection System. Genomic DNA was isolated using a 
DNeasy Blood & Tissue Kit (Qiagen) at 72 h after transfection.  
For ABE experiments, HEK293T cells (~1 × 105) were seeded on 48-well 
plates (Corning) and transfected at ~70% confluency with ABE7.10-expressing 
plasmid (750 ng) and sgRNA-expressing plasmid (250 ng) using Lipofectamine 
2000 (Thermo Fisher Scientific) according to the manufacturer’s protocol. 




2. Purification of base editor protein  
The plasmid encoding the His6-rAPOBEC1-XTEN-dCas9 protein 
(pET28b-BE1) was a gift from David Liu (Addgene plasmid #73018). The plasmid 
encoding the His6-rAPOBEC1-XTEN-nCas9 protein (BE3ΔUGI) was generated 
by site-directed mutagenesis. Rosetta expression cells (EMD Millipore) were 
transformed with His6-rAPOBEC1-XTEN-nCas9 and cultured overnight in Luria-
Bertani (LB) broth containing 100 μg/ml kanamycin and 34 μg/ml 
chloramphenicol at 37 °C. 10 ml overnight cultures of Rosetta cells containing 
His6-rAPOBEC1-XTEN-nCas9 were inoculated into 400 ml LB broth containing 
100 μg/ml kanamycin and 34 μg/ml chloramphenicol, and cultured at 30 °C until 
the OD600 reached 0.5–0.6. Cells were cooled to 16 °C for 1 h, supplemented with 
0.5 mM IPTG, and cultured for 14-18 h. 
For protein purification, cells were harvested by centrifugation at 5,000g 
for 10 min at 4 °C and lysed by sonication in 5 ml lysis buffer (50 mM NaH2PO4, 
300 mM NaCl, 1 mM DTT, and 10 mM imidazole, pH 8.0) supplemented with 
lysozyme (Sigma) and protease inhibitor (Roche complete, EDTA-free). The 
soluble lysate obtained after centrifugation at 13,000 r.p.m. for 30 min at 4 °C was 
incubated with Ni-NTA agarose resin (Qiagen) for 1 h at 4 °C. The lysate/Ni-NTA 
mixture was applied to a column and washed with a buffer (50 mM NaH2PO4, 300 
mM NaCl, and 20 mM imidazole, pH 8.0). The BE3 protein was eluted with 
elution buffer (50 mM NaH2PO4, 300 mM NaCl, and 250 mM imidazole, pH 8.0). 
The eluted protein was buffer exchanged with storage buffer (20 mM HEPES-KOH 
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(pH 7.5), 150 mM KCl, 1 mM DTT, and 20% glycerol) and concentrated with 
centrifugal filter units (Millipore). 
 
3. In vitro transcription of sgRNAs 
sgRNA was in vitro transcribed through run-off transcription reactions by 
T7 RNA polymerase (New England BioLabs). Template DNA for sgRNA contain a 
T7 RNA promoter sequence followed by protospacer and sgRNA scaffold sequence. 
sgRNA transcription templates (200 mM) were mixed with NTP (4 mM), MgCl2 
(14 mM), T7 RNA polymerase (500 units), RNase inhibitor (10 units) (New 
England BioLabs) in a reaction volume of 100 μl for overnight at 37 °C. To remove 
the template DNA after RNA synthesis, transcribed RNA were pre-incubated with 
DNase I (4 units) (New England BioLabs) and purified using RNeasy Mini Kit 
(Qiagen) according to the manufacturer’s manual.  
 
4. Base editor and USER treatment of a PCR amplicon  
The PCR amplicon (10 μg) containing the EMX1 site was first incubated 
with the purified rAPOBEC1-nCas9 protein (4 μg) and the EMX1-specific sgRNA 
(3 μg) in a reaction volume of 100 μl for 1 h at 37 °C. It was next incubated with 
USER (6 units) (New England BioLabs) for 30 min at 37 °C and then subjected to 
agarose gel electrophoresis. 
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5. Base editor and USER treatment of genomic DNA  
Genomic DNA was purified from HEK293T cells or mouse tissue with a 
DNeasy Blood & Tissue Kit (Qiagen) according to the manufacturer’s instructions. 
Genomic DNA (10 μg) was incubated with the purified rAPOBEC1-nCas9 protein 
(300 nM) and an sgRNA (900 nM) in a reaction volume of 500 μL for 8 h at 37 °C 
in a buffer (100 mM NaCl, 40 mM Tris-HCl, 10 mM MgCl2, and 100 μg/ml BSA, 
pH 7.9). After removal of sgRNA using RNase A (50 μg/mL), uracil-containing 
genomic DNA was purified with a DNeasy Blood & Tissue Kit (Qiagen). Purified 
genomic DNA (2 μg) was incubated with USER (6 units) in a reaction volume of 
100 μL at 37 °C for 3 h and, then, purified again with a DNeasy Blood & Tissue 
Kit (Qiagen). The target site was PCR-amplified using SUN-PCR blend and 
subjected to Sanger sequencing to check BE3-mediated cytosine deamination and 
USER-mediated DNA cleavage. 
 
6. Whole genome sequencing and digenome sequencing  
Genomic DNA (1 μg) was fragmented to the 400- to 500-bp range using 
the Covaris system (Life Technologies) and blunt-ended using End Repair Mix 
(Thermo Fischer). Fragmented DNA was ligated with adapters to produce libraries, 
which were then subjected to WGS using HiSeq X Ten Sequencer (Illumina) at 
Macrogen. WGS was performed at a sequencing depth of 30–40×. A DNA cleavage 
score was assigned to each nt position across the genome according to the equation. 
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DNA cleavage sites were identified using Digenome 1.0 and Digenome 2.0 
programs. The source code of the version of Digenome 2.0 used in the manuscript 
is available as up-to-date versions of the program at 
https://github.com/chizksh/digenome-toolkit2. 
For analysis of mouse WGS data, SNVs in Tyr #4 were trimmed out, 
compared with those in the WT control using the program ‘Strelka’ with the default 
‘eland’ option. The resulting putative off-target sites were compared with 
homologous sites, identified using Cas-OFFinder, with up to seven mismatches or 
with up to five mismatches and a DNA or RNA bulge. 
 
7. Targeted deep sequencing 
On-target and potential off-target sites were amplified with a KAPA HiFi 
HotStart PCR kit (KAPA Biosystems #KK2501) for deep sequencing library 
generation. For the paired-end sequencing (Figure 1) (Park et al., 2017), DNA 
library must have two adaptors including i5 & i7 index. Target DNA was amplified 
using PCR polymerase with pre-index tailed primers. After pre-indexed 
amplification, PCR products were amplified with universal index primers (Table 1). 
Amplicons were purified using column-based purification kit (MGmed). Pooled 
PCR amplicons were sequenced using MiniSeq or Miseq with TruSeq HT Dual 




8. ABE mRNA preparation 
The pET_ABE7.10_nCas9 plasmid was generated based on ABE amino 
acid sequences from David Liu’s study (Gaudelli et al., 2017). The codons were 
optimized for expression in human cells. PCR using Phusion High-Fidelity DNA 
Polymerase (Thermo Scientific) and primers (F: 5ʹ-GGT GAT GTC GGC GAT 
ATA GG-3ʹ, R: 5ʹ-CCC CAA GGG GTT ATG CTA GT-3ʹ) that were described in 
previous paper (Kim et al., 2017b) were used to prepare the ABE7.10 mRNA 
template. An in vitro RNA transcription kit (mMESSAGE mMACHINE T7 Ultra 
kit, Ambion) and a purification kit, MEGAclear kit (Ambion), were used to 
synthesize and purify the ABE7.10 mRNA. 
 
9. Animals 
Protocols involving mice used in experiments were approved by the 
Institutional Animal Care and Use Committee (IACUC) of Seoul National 
University. C57BL/6J and ICR mouse strains were used as embryo donors and 
foster mothers, respectively, and C57BL/6J, ICR, and Dmd knockout mice were 
maintained in an SPF (specific pathogen-free) facility under a 12-h dark-light cycle. 
 
10. Microinjection of mouse zygotes 
Methods for steps to prepare for microinjection, including superovulation 
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and embryo collection, were described in previous manuscript (Hur et al., 2016). A 
solution containing ABE7.10 mRNA (10 ng/μl) and sgRNA (100 ng/μl) was diluted 
with diethyl pyrocarbonate (DEPC)-treated injection buffer (0.25 mM EDTA, 10 
mM Tris, pH 7.4) (Kim et al., 2017b; Sung et al., 2014) and injected into pronuclei 
using a Nikon ECLIPSE Ti micromanipulator and a FemtoJet 4i microinjector 
(Eppendorf). After microinjection, embryos were cultured in microdrops of 
KSOM+AA medium (Millipore) at 37 °C in a humidified atmosphere consisting of 
5% CO2 in air. Two-cell-stage embryos were then transplanted into the oviducts of 
0.5-dpc (days post coitus) pseudo-pregnant foster mothers to obtain offspring. For 
in vitro analysis, we cultured microinjected zygotes for 4 days to obtain blastocysts.  
 
11. Statistical analysis 
All group results are expressed as mean ± s.e.m. unless stated otherwise. 
Comparisons between groups were made using the two-tailed Student’s t-test. 
Statistical significance as compared with controls was denoted with *P < 0.05, **P 
< 0.01, ***P < 0.001 in the figures and figure legends. Statistical analysis was 




Figure 1. Illumina sequencing library preparation protocol using PCR. (a) 
Experimental scheme for deep sequencing library preparation. The length of target 
DNA ~250bp for Miseq 300 cycle or ~450bp for Miseq 500 cycle to merge the 




Ⅲ. Results  
 
1. Editing efficiency and mismatch tolerance of BE3 are 
independent of Cas9 
 
a. Indel efficiencies of Cas9 nucleases and base-editing 
efficiencies of base editors 
First, I compared genome editing efficiencies, defined by indel 
frequencies at target sites of Cas9 nucleases, with base editing efficiencies, defined 
by single-nucleotide substitution frequencies of three different forms of base 
editors (all from(Komor et al., 2016)), at seven genomic loci in HEK293T cells 
(Figure 2a–c). Base editors induce C-to-T (C-to-G or C-to-A, to a lesser extent) 
conversions at nucleotide positions 4–8 (numbered 1–20 in the 5′ to 3′ direction in 
protospacer sequence). Because base editor 3 (BE3: rAPOBEC1–nCas9–UGI 
(uracil DNA glycosylase inhibitor), 29 ± 6%) was much more efficient than BE1 
(rAPOBEC1–dCas9, 5 ± 1%) and BE2 (rAPOBEC1–dCas9–UGI, 8 ± 2%), I 
focused on BE3 throughout this study. BE3 activities were largely independent of 
Cas9 nuclease activities. Thus, a rank order analysis showed that certain sgRNAs 






(With Desik Kim in Institute for Basic Science) 
Figure 2. Comparison of BE3-associated base editing efficiencies and Cas9-
associated indel frequencies in human cells. (a) Base editing efficiencies 
obtained with BE1 (rAPOBEC1–dCas9), BE2 (rAPOBEC1–dCas9–UGI), and BE3 
(rAPOBEC1–nCas9–UGI) at seven endogenous target sites in HEK293T cells. 
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Base editing efficiencies were measured by targeted deep sequencing. Error bars 
indicate s.e.m. (b) Cas9 nuclease-driven mutation frequencies were measured by 
targeted deep sequencing at seven endogenous target sites in HEK293T cells. (c) A 
table showing target DNA sequences and mutation frequencies. The PAM is shown 
in blue. (d) A graph showing the rank order of indel frequencies or base editing 




b. Tolerance of BE3 and Cas9 for mismatched sgRNAs 
To assess specificities of BE3 deaminases, I examined whether BE3 can 
tolerate mismatches in sgRNAs. To this end, I transfected HEK293T cells with 
plasmids encoding BE3 or Cas9 and simultaneously with sgRNAs having one to 
four mismatches and measured mutation frequencies at three endogenous sites 
(Figure 3). Overall, there was a statistically significant correlation (R2 = 0.70, 0.83, 
and 0.71 at the three sites) between Cas9-induced indel frequencies and BE3-
induced substitution frequencies (Figure 4). BE3 deaminases and Cas9 nucleases 
tolerated one-nucleotide (nt) mismatches at almost every position and 2-nt 
mismatches in the PAM-distal region but did not tolerate most of the 3-nt or 4-nt 
mismatches in either the PAM-proximal or distal regions.  
Several sgRNAs (indicated by asterisks in Figure 3) with two or three 
mismatches were highly active with BE3 but not with Cas9 or vice versa. For 
example, BE3 with the fully matched sgRNA or with a 3-nt mismatched sgRNA 
induced substitutions at comparable frequencies (33% vs. 14%) at the EMX1 site, 
whereas Cas9 with the same matched and 3-nt mismatched sgRNAs showed 
widely different indel frequencies (50% vs. 2%; Figure 2a). Conversely, BE3 with 
two 2-nt mismatched sgRNAs was poorly active (substitution frequencies <1%), 
whereas Cas9 with the same mismatched sgRNAs was highly active (indel 
frequencies >10%) (Figure 2a). These results indicate that the tolerance of Cas9 
nucleases and BE3 deaminases for mismatched sgRNAs can differ and imply that 
BE3 and Cas9 could have separate sets of off-target sites in the genome, calling for 











(By Desik Kim in Institute for Basic Science) 
Figure 3. Tolerance of BE3 and Cas9 for mismatched sgRNAs. Mismatched 
sgRNAs that differed from the EMX1 (a), HBB (b), and RNF2 (c) target sites by 1–
4 nucleotides were tested in HEK293T cells. Indel frequencies and cytosine 
conversion frequencies were measured using targeted deep sequencing. The PAM 
is shown in blue. Red or black asterisks indicate mismatched sgRNAs that were 
highly active with BE3 but poorly active with Cas9 or vice versa, respectively. 






(With Desik Kim in Institute for Basic Science) 
Figure 4. Correlation between indel frequencies associated with Cas9 
nucleases and base editing frequencies associated with BE3 using mismatched 
sgRNAs at the EMX1 (a), HBB (b), and RNF2 (c) sites. The red dots indicate 
mismatched sgRNAs with which the relative frequency of BE3-associated base 
editing was more than three times higher than the relative frequency of Cas9 
nuclease-associated indels. The blue dots indicate sgRNAs with which the relative 
frequency of Cas9 nuclease-associated indels was more than three times higher 




2. Digenome-seq to identify BE3 off-target sites in human the 
genome 
 
a. DSB generation of BE3-treated-DNA for Digenome-seq 
analysis 
Several different cell-based methods, which include GUIDE-seq (Tsai et 
al., 2015), HTGTS (Frock et al., 2015), BLESS (Crosetto et al., 2013; Ran et al., 
2015), and IDLV capture (Gabriel et al., 2011; Wang et al., 2015) have been 
developed and used for identifying genome-wide off-target sites at which Cas9 
nucleases induce DSBs. None of these methods, at least in their present forms, are 
suitable for assessing the genome-wide specificities of programmable deaminases, 
simply because deaminases do not yield DSBs. 
DSBs could be produced at deaminated, uracil-containing sites in vitro 
using appropriate enzymes and that these DNA cleavage sites could be identified 
via Digenome-seq, an in vitro method that have used for assessing genome-wide 
specificities of Cas9 and Cpf1 nucleases (Kim et al., 2015; Kim et al., 2016a; Kim 
et al., 2016b). To test this idea, first, a PCR amplicon containing a target sequence 
were incubated with the recombinant rAPOBEC1–nCas9 protein, a derivative of 
BE3 with no UGI domain (BE3ΔUGI), and its sgRNA in vitro to induce C-to-U 
conversions and a nick in the Watson and Crick strands, respectively. Then with 
USER (uracil-specific excision reagent), a mixture of Escherichia coli uracil DNA 
glycosylase (UDG) and DNA glycosylase-lyase endonuclease VIII, generate a gap 
at the location of the uracils, giving rise to a composite DSB (Figure 5a). Indeed, 
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the PCR amplicon was cleaved, when incubated with both BE3ΔUGI and USER 
(Figure 5b). 
To investigate whether Digenome-seq could be used to assess genome-
wide target specificities of BE3ΔUGI deaminases, human genomic DNA, purified 
from HEK293T cells, was incubated with each of seven BE3ΔUGI 
ribonucleoproteins (RNPs) (300 nM rAPOBEC1–nCas9 protein and 900 nM each 
of seven different sgRNAs) for 8 h (Figure 6) and then with USER for 3 h (Figure 
5a). C-to-U conversions induced by BE3ΔUGI and uracil removal and DNA 
cleavage by USER were confirmed by quantitative real-time PCR (Figure 7) and 
Sanger sequencing (Figure 5c). Each genomic DNA sample was subjected to whole 
genome sequencing (WGS) after end repair and adaptor ligation (Figure 5a). After 
sequence alignment to the human reference genome (hg19), alignment patterns at 
each on-target site were checked using integrative genomics viewer (IGV). 
Uniform alignments of sequence reads, signature patterns associated with DSBs 






(By Desik Kim in Institute for Basic Science) 
Figure 5. Digenome-seq to identify BE3 off-target sites in the human genome. 
(a) Overview of BE3ΔUGI Digenome-seq. BE3ΔUGI-mediated uracil-containing 
sites were cleaved by USER, a mixture of E. coli uracil DNA glycosylase (UDG) 
and DNA glycosylase-lyase endonuclease VIII. Black and red arrowheads indicate 
the positions of phosphodiester bonds cleaved by the Cas9 nickase and USER, 
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respectively. (b) The PCR product was cleaved, when treated with both BE3ΔUGI 
and USER. (c) Sanger sequencing results showing C-to-U conversions by 
BE3ΔUGI and DNA cleavage by USER. (d) IGV image showing straight 





(By Desik Kim in Institute for Basic Science) 
Figure 6. SDS-Polyacrylamide gel showing the integrity of Cas9 and 






(By Desik Kim in Institute for Basic Science) 
Figure 7. Quantitative real-time PCR showing almost complete cleavage of 





(By Desik Kim in Institute for Basic Science) 
Figure 8. IGV images showing straight alignments of sequence reads at the 6 




b. Genome-wide off-target sites of BE3 revealed by 
Digenome-seq 
To identify BE3ΔUGI off-target sites in the human genome, DNA 
cleavage score (Figure 9), based on the number of sequence reads whose 5′ ends 
aligned at a given position, was assigned to each nt position across the genome and 
listed all the sites with scores >2.5, a cutoff value used for finding off-target sites of 
Cas9 nucleases with the same set of seven sgRNAs in previous study (Kim et al., 
2016b) (Figure 10 and Table 1). Notably, only between 1 and 24 (8 ± 3) cleavage 
sites were observed for the seven BE3ΔUGI deaminases (plus USER) in human 
genomic DNA in vitro, far fewer than we did for Cas9 nucleases with the same set 
of sgRNAs (70 ± 30 sites) in a multiplex Digenome-seq analysis (Kim et al., 2016b) 
(Figure 11). This means that BE3ΔUGI has far fewer potential, not necessarily 
genuine, off-target sites than does Cas9. Sequence logos, obtained by comparing 
Digenome-identified sites, showed that both the PAM-distal and proximal regions 
contributed to the specificities of BE3ΔUGI deaminases (Figure 10c,d). 
To improve the computer program (Digenome 2.0) for identifing potential 
off-target sites more comprehensively, the number of positions whose DNA 
cleavage scores over a cutoff value were counted for range from 0.0001 to 10. And 
the number of PAM (5′-NGN-3′ or 5′-NNG-3′)-containing sites with ten or fewer 
mismatches were counted, compared to the on-target site, among the positions with 
scores over the cutoff value (Figure 12). WGS data obtained using intact genomic 
DNA, which had not been treated with BE3ΔUGI and USER and thus served as a 
negative control, did not yield any false-positive sites with cutoff score 0.1 (Figure 
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12). Digenome 2.0 as cutoff score 0.1 were able to identify many additional 
BE3ΔUGI- and Cas9-associated DNA cleavage sites, including two sites that had 
been missed in previous study (Kim et al., 2016b) but had been captured by both 
HTGTS (Frock et al., 2015) and GUIDE-seq (Tsai et al., 2015) using the EMX1-
specific Cas9. Using Digenome 2.0, BE3ΔUGI deaminases induced base 
conversions in vitro at 1–67 (18 ± 9) sites, whereas Cas9 nucleases cleaved 
genomic DNA at 30–241 (90 ± 30) sites (Figure 13). 
Potential off-target sites of BE3ΔUGI- and Cas9-associated sites were 
carefully examined. Regardless of the number of mismatches, fewer homologous 
sites were identified by Digenome-seq when BE3ΔUGI was used than when Cas9 
was used (Figure 14). There was a statistically significant correlation (R2 = 0.97 
(score > 2.5, Digenome 1.0) or R2 = 0.86 (Digenome 2.0)) between the number of 
Cas9- and BE3ΔUGI-associated sites (Figure 15a,b), suggesting that sgRNAs were 
the primary determinants of both Cas9 and BE3ΔUGI specificities. Also, there was 
a strong correlation (R2 = 0.94 (Digenome 1.0) or 0.95 (Digenome 2.0)) between 
the number of BE3ΔUGI-associated, Digenome-captured sites and the number of 
homologous sites with ≤6 mismatches in the human genome (defined as 
“orthogonality” in ref. 7) (Figure 15c,d). 
Some off-target sites were associated either with BE3ΔUGI alone or with 
Cas9 alone. 69% (18/26) of the sites associated with BE3ΔUGI alone had missing 
or extra nucleotides, compared to their respective on-target sites, producing, 
respectively, an RNA or DNA bulge at the DNA–gRNA interface (Lin et al., 2014) 
(Table 1). By contrast, these bulge-type off-target sites were rare among Cas9-
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associated sites. Thus, just 4% (25/647) of sites associated with Cas9 had missing 
or extra nucleotides. Also, 13% (73/548) of sites associated with Cas9 alone had no 
cytosines at positions 13–17 counting from the PAM, the window of BE3ΔUGI-





(By Desik Kim in Institute for Basic Science) 






(By Desik Kim in Institute for Basic Science) 
Figure 10. Genome-wide BE3 off-target sites revealed by Digenome-seq. (a,b) 
Genome-wide circos plots representing DNA cleavage scores for EMX1 (a) and 
HBB (b) obtained with intact genomic DNA (gray) and genomic DNA digested 
with BE3ΔUGI and USER (blue) or with Cas9 (red). Arrows indicate on-target 
sites. (c,d) Sequence logos for EMX1 (c) and HBB (d) obtained via WebLogo using 





Table 1. Digenome-captured sites of 7 sgRNAs. PAM sequences are shown in 






Chr Position DNA cleavage Score DNA seq at a cleavage sites Bulge
EMX1_1 chr15 44109763 30.53 GAGTCtaAGCAGAAGAAGAAGAG x
EMX1_2 chr11 62365273 26.44 GAaTCCaAGCAGAAGAAGAgAAG x
EMX1_3 chr5 9227162 23.66 aAGTCtGAGCAcAAGAAGAATGG x
EMX1_4 chr2 73160998 14.55 GAGTCCGAGCAGAAGAAGAAGGG x
EMX1_5 chr4 131662222 11.14 GAaTCCaAG-AGAAGAAGAATGG RNA bulge
EMX1_6 chr8 128801258 9.60 GAGTCCtAGCAGgAGAAGAAGAG x
EMX1_7 chr19 24250503 8.35 GAGTCCaAGCAGtAGAgGAAGGG x
EMX1_8 chr1 4515013 8.12 GtGTCCtAG-AGAAGAAGAAGGG RNA bulge
EMX1_9 chr1 23720618 5.96 aAGTCCGAGgAGAgGAAGAAAGG x
EMX1_10 chr2 219845072 5.47 GAGgCCGAGCAGAAGAAagACGG x
EMX1_11 chr8 102244551 4.70 agtTCCaAGCAGAAGAAGcATGG x
EMX1_12 chr3 45605387 3.11 GAGTCCacaCAGAAGAAGAAAGA x
EMX1_13 chr16 12321159 3.01 GAGTCCaAG-AGAAGAAGtgAGG RNA bulge
EMX1_14 chr9 111348573 1.56 GAGTCCttG-AGAAGAAGgAAGG RNA bulge
EMX1_15 chr3 5031614 1.50 GAaTCCaAGCAGgAGAAGAAGGA x
EMX1_16 chr14 31216733 1.34 GtacCaGAG-AGAAGAAGAgAGG RNA bulge
EMX1_17 chr14 48932119 1.16 GAGTCCcAGCAaAAGAAGAAAAG x
EMX1_18 chr11 107812992 1.04 aAGTCCaAGt-GAAGAAGAAAGG RNA bulge
EMX1_19 chr12 106646090 1.03 aAGTCCatGCAGAAGAgGAAGGG x
EMX1_20 chr2 71969823 0.80 GAGTCCtAG-AGAAGAAaAAGGG RNA bulge
EMX1_21 chr3 145057362 0.48 GAGTCCct-CAGgAGAAGAAAGG RNA bulge
EMX1_22 chr6 9118799 0.45 acGTCtGAGCAGAAGAAGAATGG x
EMX1_23 chr1 59750259 0.27 GAGTtCcAGaAGAAGAAGAAGAG x
EMX1_24 chr11 79484079 0.22 GAGTCCtAa-AGAAGAAGcAGGG RNA bulge
EMX1_25 chr9 135663403 0.21 cAGTCCaAaCAGAAGAgGAATGG x
EMX1
Chr Position DNA Cleavage Score DNA seq at a cleavage sites Bulge
HBB_1 chr11 5248214 17.68 CTTGCCCCACAGGGCAGTAACGG x
HBB_2 chr17 8370252 13.64 tTgctCCCACAGGGCAGTAAACG x
HBB_3 chr12 124803834 10.88 gcTGCCCCACAGGGCAGcAAAGG x
HBB_4 chrX 75006256 2.34 gTgGCCCCACAGGGCAGgAATGG x
HBB_5 chr12 93549201 0.55 aTTGCCCCACgGGGCAGTgACGG x
HBB_6 chr10 95791920 0.27 acTctCCCACAaGGCAGTAAGGG x
HBB_7 chr9 104595883 0.18 tcaGCCCCACAGGGCAGTAAGGG x
HBB
Chr Position DNA Cleavage Score DNA seq at a cleavage sites Bulge
HEK2_1 chr4 90522183 18.27 GAACACAAtGCATAGAtTGCCGG x
HEK2_2 chr5 87240613 7.54 GAACACAAAGCATAGACTGCGGG x









Chr Position DNA Cleavage Score DNA seq at a cleavage sites Bulge
RNF2_1 chr1 185056773 27.66 GTCATCTTAGTCATTACCTGAGG x
RNF2
Chr Position DNA Cleavage Score DNA seq at a cleavage sites Bulge
FANCF_1 chr10 73463135 13.34 tGAATCCCaTCTcCAGCACCAGG x
FANCF_2 chr11 22647338 7.04 GGAATCCCTTCTGCAGCACCTGG x
FANCF_3 chr10 43410030 6.53 GGAgTCCCTcCTaCAGCACCAGG x
FANCF_4 chr10 37953199 5.67 GGAgTCCCTcCTaCAGCACCAGG x
FANCF_5 chr11 47554037 5.13 GGAATCCCTTCTaCAGCAtCCTG x
FANCF_6 chr16 49671025 3.00 GGAgTCCCTcCTGCAGCACCTGA x
FANCF_7 chr18 8707528 1.26 GGAAcCCCgTCTGCAGCACCAGG x
FANCF_8 chr7 44076496 0.95 GtctcCCCTTCTGCAGCACCAGG x
FANCF_9 chr9 113162294 0.46 aaAATCCCTTCcGCAGCACCTAG x
FANCF_10 chr15 49119756 0.42 tGtATttCTTCTGCctCAggCTG x
FANCF_11 chr2 54853314 0.39 GGAATatCTTCTGCAGCcCCAGG x
FANCF_12 chr8 21374810 0.37 GagtgCCCTgaaGCctCAgCTGG x
FANCF_13 chrX 86355179 0.35 accATCCCTcCTGCAGCACCAGG x
FANCF_14 chr3 35113165 0.20 tGAATCCtaaCTGCAGCACCAGG x
FANCF_15 chr10 3151994 0.13 ctctgtCCTTCTGCAGCACCTGG x
FANCF
Chr Position DNA Cleavage Score DNA seq at a cleavage sites Bulge
HEK3_1 chr1 47005705 29.27 aGCtCAGACTGAGCAaGTGAGGG x
HEK3_2 chr9 110184636 11.38 GGCCCAGACTGAGCACGTGATGG x
HEK3_3 chr19 882560 10.90 GGCCCAGA--GAGCACGTGtGGG RNA bulge
HEK3_4 chr15 79749930 3.03 caCCCAGACTGAGCACGTGcTGG x
HEK3_5 chr17 34954539 2.10 GGCCCa-ACTGAGCAaGTGATGG RNA bulge
HEK3_6 chrX 114764149 1.66 aGaCCAGACTGAGCAaGaGAGGG x
HEK3_7 chr6 73097166 0.15 GGCCactcaTGgcCACaTacTGG x
HEK3
Chr Position DNA Cleavage Score DNA seq at a cleavage sites Bulge
HEK4_1 chr20 31349772 19.26 GGCACTGCGGCTGGAGGTGGGGG x
HEK4_2 chr6 160517881 15.45 GGCACTGCtGCTGGgGGTGGTGG x
HEK4_3 chr6 168787137 15.37 GGCACTGCa-CTGGAGGTtGTGG RNA bulge
HEK4_4 chr19 33382081 13.83 GGCtCTGCGGCTGGAGGgGGTGG x
HEK4_5 chr20 60080553 12.71 aGCACTGCaGaTGGAGGaGGCGG x
HEK4_6 chr5 141232853 10.87 GGCACTGCGGCaGGgaGgaGGGG x
HEK4_7 chr20 60010562 10.51 tGCACTGCGGCcGGAGGaGGTGG x
HEK4_8 chr13 70136736 8.76 GGCACT-gGGCTGaAGGTaGAGG RNA bulge
HEK4_9 chr20 1151854 8.41 GGCACTGtGGCTGcAGGTGGAGG x
HEK4_10 chr15 71686928 7.70 tGCtCTGCGGCaGGAGGaGGAGG x
HEK4_11 chr7 1397398 6.71 aGCACTGCaGCTGGgaGTGGAGG x
HEK4_12 chr20 45343010 6.57 GGCACTGaGGgTGGAGGTGGGGG x
HEK4_13 chr8 20854500 5.57 GGCACTGgGGCTGGAGacGGGGG x
HEK4_14 chr7 54561437 5.40 aGgACTGCGGCTGGgGGTGGTGG x





Chr Position DNA Cleavage Score DNA seq at a cleavage sites Bulge
HEK4_16 chr13 27629410 4.40 GGCACTGgGGtTGGAGGTGGGGG x
HEK4_17 chr7 110143150 3.69 GcCACTGCaGCTaGAGGTGGAGG x
HEK4_18 chr7 139244406 3.59 GcCACTGCGaCTGGAGGaGGGGG x
HEK4_19 chr19 2474643 3.56 GGCACTG-GGCTGGAGGcGGGGG RNA bulge
HEK4_20 chr2 6961255 3.17 aGCtCTGCGGCaGGAGtTGGAGG x
HEK4_21 chr17 75429280 2.90 GaCACcaCGGCTGGAGaTGGTGG x
HEK4_22 chr7 17979717 2.66 GcactgGCaGCcGGAGGTGGTGG DNA bulge
HEK4_23 chr9 5020590 2.64 tGCACTGCaGCTGcAGGTGGAGG x
HEK4_24 chrX 122479548 2.52 GGCACTG-GGCTGGAGaTGGAGG RNA bulge
HEK4_25 chr12 104739608 2.48 ccttCTGCGGCTGGAaGTGGTGG x
HEK4_26 chr17 40693638 2.38 GcactgcaGGCaGGAGGTGaGTG DNA bulge
HEK4_27 chr8 144781301 2.38 GaCACTGCaGCTGGAGGTGGGGT x
HEK4_28 chr9 74103955 2.36 GGCACTGCaGCaGGgGaTGGGGG x
HEK4_29 chr18 37194558 2.31 GGCACTGCGGgTGGAGGcGGGGG x
HEK4_30 chr20 60895671 2.12 GGCACaGCaGCTGGAGGTGcTGG x
HEK4_31 chr12 113935460 1.63 GGCcCTGCGGCTGGAGaTatGGG x
HEK4_32 chrX 70597642 1.57 GaCACTGC-tCTGGAGGTGGTGG RNA bulge
HEK4_33 chr15 41044242 1.31 GGCgCTGCGGCgGGAGGTGGAGG x
HEK4_34 chr17 176302 1.18 tGCACTGtGGCTGGAGaTGGGGG x
HEK4_35 chr10 77103119 1.15 GGCAtcaCGGCTGGAGGTGGAGG x
HEK4_36 chr7 134872032 0.93 aGCACTGtGGCTGGgGGaGGCGG x
HEK4_37 chr9 133039175 0.86 GtCACTGCaGCTGGAGGaGGGGG x
HEK4_38 chr10 73435248 0.79 GtaACTGCGGCTGGcGGTGGTGG x
HEK4_39 chr14 21993455 0.78 GGtACaGCGGCTGGgGGaGGCGG x
HEK4_40 chr17 29815563 0.59 GGCgCTGCGGCcGGAGGTGGGGC x
HEK4_41 chr16 50300346 0.56 aGCACTGtGGCTGGgGGaGGGGG x
HEK4_42 chr11 78127584 0.53 tGCACTGCaGCTGGAGGcaaCGG x
HEK4_43 chr19 1295086 0.52 GaCACTGaGGCaGGAGGTGGGGG x
HEK4_44 chr2 162283033 0.51 GGCAtctgGGCTGGgGGTaGGGG x
HEK4_45 chr20 24376056 0.47 GGCACTGaGaCcaGAGGTGGTGG x
HEK4_46 chr16 1029977 0.42 GGCACTGCaGacGGAGGTGtGGG x
HEK4_47 chr19 47503406 0.39 GGCACTG-GGCTGGAGGgGaGAG RNA bulge
HEK4_48 chr2 231467380 0.39 GGCACTGCaGCTGGgGGTtGGTG x
HEK4_49 chr10 13692636 0.38 GGCACTGgGGCTGGgGGaGGGGG x
HEK4_50 chr1 32471659 0.34 GGCACTtCaGCTGGAGGcaGAGG x
HEK4_51 chr17 8634933 0.33 GGCACat-GGaTGGAGGTGGAGG RNA bulge
HEK4_52 chr6 83388605 0.30 aGCACTGtGG-TGGAGGTGGAGG RNA bulge
HEK4_53 chr10 27700491 0.29 GGCACTG-GGtTGGgGGTGGTGG RNA bulge
HEK4_54 chr1 143662284 0.27 GGCACat-GGCTGGgGGTGGTGG RNA bulge
HEK4_55 chr16 49777696 0.22 tGCACTGCGaCTGGAGGgaGAGG x
HEK4_56 chr19 38616186 0.19 GGCACTGaGaCTGGgGGTGGGGG x
HEK4_57 chr10 126752487 0.18 GGCACTGCaGCctGgGGgtGGGG x
HEK4_58 chr16 28266968 0.17 GGCtCTtCGGCTGGAGGTaGCGG x
HEK4_59 chr2 149886210 0.15 GaCACTG-GGCTGGAGGTtGCGG RNA bulge
HEK4_60 chr20 37471343 0.15 aGCACTGtGcCTGGgGGTGGGGG x
HEK4_61 chr12 53453556 0.13 tGgACTGCGGCTGGAGagGGAGG x
HEK4_62 chr15 30501337 0.13 GGCACTG-GGCTGGAtGTGGTGG RNA bulge
HEK4_63 chr5 139284047 0.12 GGCACTGaGGCTGcAGGcGGCGG x
HEK4_64 chr8 119227145 0.12 GGCACaatGGCTGGAGGTGaAGG x
HEK4_65 chr14 95761249 0.11 GGCACTctGGCTGGAGcTGGGGG x
HEK4_66 chr3 23651529 0.11 GGCACaGCaGgTGGAGGTGGAGG x





(By Desik Kim in Institute for Basic Science) 
Figure 11. Venn diagrams showing the number of sites with DNA cleavage 
scores over 2.5 identified by Digenome-seq of Cas9 nuclease- and BE3ΔUGI-




(By Desik Kim in Institute for Basic Science) 
Figure 12. The number of total sites (upper) and the number of PAM-
containing sites with ten or fewer mismatches (lower) for a range of DNA 
cleavage scores. Intact human genomic DNA (left) and genomic DNA digested by 
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Figure 13. Venn diagrams showing the number of PAM-containing 
homologous sites with DNA cleavage scores over 0.1 identified by Digenome-
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Figure 14. Fraction of homologous sites captured by Digenome-seq. Blue bars 
represent the number of homologous sites that differ from on-target sites by up to 6 
nt. Red squares (BE3ΔUGI) and green triangles (Cas9) represent the fraction of 







(By Desik Kim in Institute for Basic Science) 
Figure 15. Analysis of correlations revealed by Digenome 1.0 and Digenome 
2.0. (a, b) Correlation between the number of BE3ΔUGI- and Cas9-associated sites 
identified by Digenome 1.0 (a) and Digenome 2.0 (b). (c, d) Correlation between 
the number of BE3ΔUGI-associated sites identified by Digenome 1.0 (c) or 
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Figure 16. Examples of Digenome-captured off-target sites associated only 
with Cas9, which contain no cytosines at positions 13-17. The PAM is shown in 





3. Validation of genome-wide BE3 off-target sites 
To validate off-target effects at BE3ΔUGI-associated sites identified by 
Digenome-seq, I performed targeted deep sequencing and measured BE3-induced 
substitution frequencies and Cas9-induced indel frequencies in HEK293T cells 
(Figure 17 and Table 2). I analyzed a total of 75 sites identified using seven 
sgRNAs and observed BE3-induced point mutations at 50 sites, including all seven 
on-target sites, with frequencies above noise levels caused by sequencing errors 
(typically in the range of 0.1~1%), resulting in a validation rate of 67%. It is 
possible that BE3 can still induce mutagenesis at the other BE3ΔUGI-associated, 
Digenome-captured sites with frequencies below background noise levels. Notably, 
I was able to identify BE3 off-target sites at which base editing was detected with a 
frequency of 0.1%, demonstrating that Digenome-seq is a highly sensitive method. 
Cas9 nucleases detectably induced indels at 70% (44/63) of the sites associated 
with both Cas9 and BE3ΔUGI but failed to do so at each of the 12 sites associated 
with BE3ΔUGI alone (Table 2). Likewise, BE3 did not cause detectable 
substitutions at 24 Digenome-captured sites that were associated with Cas9 
nucleases alone using three different sgRNAs (Table 3). Furthermore, six BE3s did 
not induce base editing at 57 Digenome-negative sites with ≤3 mismatches, 
identified using Cas-OFFinder (Bae et al., 2014) (Table 4). 
Frequencies of BE3-induced substitutions were well-correlated with those 
of Cas9-mediated indels (R2 = 0.92 (EMX1) or 0.89 (HBB)) (Figure 17a,b). 
Nevertheless, there were many off-target sites validated in the BE3 but not by Cas9 
data. 64% (7/11) of these validated, BE3-exclusive off-target sites had a missing 
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nucleotide, compared to their respective on-target sites. These results show that 
Cas9 and BE3 off-target sites largely overlapped with each other but that there 
were off-target sites exclusively associated with Cas9 alone or BE3 alone (Figure 
17a,b and Table 2). This discrepancy can be attributed to the fact that BE3 and 
Cas9 catalyze different chemical reactions and induce site-specific mutations via 
different repair mechanisms. 
To compare BE3 off-target effects and Cas9 off-target effects 
quantitatively, an off-target effect index (OTI) (Kim et al., 2016b) for each of the 
seven sgRNAs was obtained by dividing cumulative mutation frequencies at 
validated off-target sites by the on-target mutation frequency (Table 5). BE3 OTIs, 
which ranged from 0.0 to 1.7, were always smaller than Cas9 OTIs, suggesting that 
BE3 deaminases are more specific than Cas9 nucleases in general. 
In addition to human genomic DNA, Digenome-seq using mouse genomic 
DNA were carried out to test whether the BE3ΔUGI deaminase targeted to the 
Dmd gene to create mutant mice with nonsense or missense mutations (Kim et al., 
2017b) was highly specific in the mouse genome (Figure 18a). Two candidate sites 
with two mismatches and a missing nucleotide were identified in addition to the 
on-target site but were invalidated by targeted deep sequencing (Figure 18b,c). 
Thus, no point mutations were detectably induced at these two sites in a mouse cell 





Figure 17. Validation of genome-wide BE3 off-target sites revealed by 
Digenome-seq. (a,b) Scatterplots for EMX1 (a) and HBB (b) of BE3-mediated 
substitution frequencies vs. Cas9-mediated indel frequencies determined using 
targeted deep sequencing. Circled red dots indicate off-target sites validated by 
BE3 but invalidated by Cas9. (c,d) BE3 off-target sites for EMX1 (c) and HBB (d) 
validated in HEK293T cells by targeted deep sequencing. PAM sequences are 
shown in blue. Mismatched bases are shown in red. Dashes indicate RNA bulges. 
Error bars indicate s.e.m. (n = 3). 
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Table 2. Mutation frequencies of Cas9 and BE3 at on-target and off-target 




(-) RGEN  RGEN BE3 Cas9
G A G T C C G A G C A G A A G A A G A A G G G
Untreated 0.04 0.06 0.15
BE1 8.49 4.72 0.08
BE2 11.08 10.72 0.09
BE3 49.17 45.06 0.10





G A a T C C a A G C A G A A G A A G A g A A G
Untreated 0.08 0.08 0.07
BE1 0.65 0.31 0.06
BE2 0.32 0.32 0.07
BE3 0.84 0.81 0.07
a A G T C t G A G C A c A A G A A G A A T G G
Untreated 0.02 0.07 0.06
BE1 0.02 0.07 0.04
BE2 0.02 0.05 0.05
BE3 0.13 0.07 0.05





G A G T C C t A G C A G g A G A A G A A G A G
Untreated 0.02 0.04 0.04
BE1 0.06 0.07 0.07
BE2 0.07 0.08 0.05
BE3 2.43 2.40 0.04
G A G T C C a A G C A G t A G A g G A A G G G
Untreated 0.03 0.06 0.06
BE1 0.07 0.10 0.07
BE2 0.03 0.06 0.09
BE3 0.05 0.09 0.07










G A G g C C G A G C A G A A G A A a g A C G G
Untreated 0.14 0.10 0.13
BE1 0.44 0.24 0.16
BE2 0.51 0.48 0.15
BE3 3.45 3.70 0.17
a g t T C C a A G C A G A A G A A G c A T G G
Untreated 0.06 0.05 0.07 0.06
BE1 1.19 0.44 0.08 0.07
BE2 0.46 0.43 0.05 0.07
BE3 0.74 0.62 0.06 0.07
G A G T C C a c a C A G A A G A A G A A A G A
Untreated 0.08 0.26 0.11 0.11
BE1 0.08 0.24 0.11 0.11
BE2 0.08 0.23 0.10 0.10
BE3 0.17 0.33 0.17 0.10










G A a T C C a A G C A G g A G A A G A A G G A
Untreated 0.04 0.07 0.05
BE1 0.03 0.08 0.06
BE2 0.04 0.07 0.06
BE3 0.14 0.18 0.05





G A G T C C c A G C A a A A G A A G A A A A G
Untreated 0.10 0.19 0.09 0.07
BE1 0.13 0.17 0.09 0.05
BE2 0.10 0.20 0.06 0.03
BE3 0.11 0.20 0.07 0.07





a A G T C C a t G C A G A A G A g G A A G G G
Untreated 0.03 0.07 0.10
BE1 0.17 0.10 0.12
BE2 0.09 0.14 0.08
BE3 0.24 0.30 0.12






Base editing efficiency, C to other bases (%)


















































G A G T C C c t - C A G g A G A A G A A A G G
Untreated 0.16 0.08 0.07 0.03
BE1 0.15 0.10 0.06 0.04
BE2 0.20 0.13 0.11 0.05
BE3 0.20 0.12 0.10 0.06
a c G T C t G A G C A G A A G A A G A A T G G
Untreated 0.14 0.04 0.11
BE1 0.17 0.36 0.10
BE2 0.13 0.14 0.11
BE3 0.15 0.62 0.12





G G A G T C C t A a - A G A A G A A G c A G G G
Untreated 0.05 0.18 0.11
BE1 0.04 0.18 0.12
BE2 0.05 0.19 0.11
BE3 0.05 0.22 0.12
c A G T C C a A a C A G A A G A g G A A T G G
Untreated 0.11 0.05 0.11 0.11
BE1 0.08 0.10 0.10 0.10
BE2 0.10 0.06 0.10 0.11











(-) RGEN  RGEN BE3 Cas9
G G A A T C C C T T C T G C A G C A C C T G G
Untreated 0.06 0.10 0.04 0.03 0.13 0.13 0.05 0.04
BE1 0.81 0.39 0.42 0.07 0.12 0.13 0.06 0.03
BE2 2.11 2.06 1.97 0.39 0.14 0.09 0.07 0.02
BE3 10.26 9.44 9.28 4.12 0.18 0.12 0.05 0.04
t G A A T C C C a T C T c C A G C A C C A G G
Untreated 0.07 0.10 0.08 0.03 0.04 0.04 0.07 0.04 0.07
BE1 0.07 0.10 0.09 0.03 0.05 0.05 0.09 0.03 0.06
BE2 0.10 0.10 0.12 0.03 0.02 0.06 0.07 0.02 0.08
BE3 0.16 0.16 0.18 0.06 0.05 0.07 0.09 0.03 0.07
G G A g T C C C T c C T a C A G C A C C A G G
Untreated 0.06 0.09 0.05 0.08 0.03 0.06 0.07 0.06 0.14
BE1 0.06 0.09 0.06 0.08 0.03 0.06 0.06 0.07 0.13
BE2 0.06 0.10 0.05 0.08 0.04 0.05 0.07 0.07 0.15
BE3 0.20 0.23 0.18 0.16 0.06 0.08 0.06 0.07 0.18
G G A g T C C C T c C T a C A G C A C C A G G
Untreated 0.06 0.05 0.05 0.05 0.06 0.06 0.03 0.03 0.06
BE1 0.06 0.05 0.05 0.02 0.07 0.07 0.03 0.03 0.05
BE2 0.07 0.06 0.03 0.05 0.06 0.07 0.02 0.04 0.06
BE3 0.11 0.09 0.12 0.05 0.06 0.07 0.04 0.04 0.04
G G A A T C C C T T C T a C A G C A t C C T G
Untreated 0.09 0.07 0.05 0.03 0.07 0.03 0.03
BE1 0.07 0.06 0.04 0.03 0.07 0.03 0.03
BE2 0.08 0.05 0.06 0.03 0.06 0.05 0.03
BE3 0.10 0.07 0.05 0.03 0.07 0.03 0.02
G G A g T C C C T c C T G C A G C A C C T G A
Untreated 0.04 0.04 0.04 0.02 0.04 0.09 0.06 0.02 0.04
BE1 0.05 0.05 0.02 0.02 0.04 0.12 0.04 0.05 0.05
BE2 0.04 0.05 0.05 0.03 0.06 0.11 0.06 0.05 0.05
BE3 0.13 0.09 0.09 0.05 0.06 0.12 0.06 0.05 0.03
G G A A c C C C g T C T G C A G C A C C A G G
Untreated 0.03 0.07 0.07 0.06 0.03 0.20 0.05 0.03 0.07
BE1 0.05 0.06 0.04 0.07 0.01 0.21 0.05 0.02 0.05
BE2 0.04 0.08 0.05 0.08 0.02 0.23 0.06 0.02 0.05
BE3 1.06 1.07 1.07 1.02 0.71 0.22 0.07 0.03 0.07
G t c t c C C C T T C T G C A G C A C C A G G
Untreated 0.02 0.03 0.04 0.02 0.05 0.03 0.11 0.03 0.02 0.03
BE1 0.02 0.02 0.03 0.04 0.05 0.03 0.08 0.04 0.02 0.04
BE2 0.01 0.02 0.02 0.05 0.05 0.02 0.09 0.03 0.02 0.04
BE3 0.02 0.02 0.04 0.04 0.08 0.03 0.10 0.03 0.02 0.03
a a A A T C C C T T C c G C A G C A C C T A G
Untreated 0.07 0.02 0.04 0.05 0.06 0.05 0.04 0.05 0.06
BE1 0.08 0.03 0.04 0.04 0.07 0.04 0.04 0.05 0.04
BE2 0.08 0.02 0.03 0.03 0.07 0.04 0.04 0.04 0.06
BE3 0.10 0.04 0.05 0.05 0.06 0.06 0.04 0.05 0.03





G G A A T a t C T T C T G C A G C c C C A G G
Untreated 0.03 0.05 0.22 0.03 0.05 0.05 0.10
BE1 0.03 0.04 0.23 0.03 0.06 0.05 0.09
BE2 0.03 0.04 0.21 0.03 0.06 0.07 0.09
BE3 0.04 0.03 0.21 0.02 0.06 0.05 0.09





a c c A T C C C T c C T G C A G C A C C A G G
Untreated 0.07 0.06 0.04 0.04 0.04 0.06 0.05 0.10 0.03 0.08 0.04
BE1 0.14 0.07 0.07 0.04 0.05 0.06 0.04 0.10 0.04 0.06 0.05
BE2 0.11 0.07 0.04 0.03 0.04 0.06 0.04 0.12 0.04 0.05 0.05
BE3 0.13 0.08 0.15 0.15 0.14 0.13 0.09 0.10 0.04 0.06 0.04
t G A A T C C t a a C T G C A G C A C C A G G
Untreated 0.09 0.05 0.04 0.09 0.06 0.08 0.06
BE1 0.09 0.04 0.05 0.10 0.06 0.10 0.07
BE2 0.07 0.05 0.04 0.07 0.06 0.09 0.06
BE3 0.10 0.08 0.03 0.11 0.07 0.10 0.07
c t c t g t C C T T C T G C A G C A C C T G G
Untreated 0.03 0.04 0.05 0.02 0.02 0.06 0.02 0.01 0.03
BE1 0.03 0.02 0.04 0.02 0.02 0.06 0.03 0.02 0.04
BE2 0.04 0.03 0.04 0.03 0.02 0.05 0.03 0.02 0.04




Base editing efficiency, C to other bases (%)








































(-) RGEN  RGEN BE3 Cas9
C T T G C C C C A C A G G G C A G T A A C G G
Untreated 0.05 0.08 0.03 0.05 0.04 0.04 0.08
BE1 0.04 0.08 0.14 0.17 0.08 0.05 0.07
BE2 0.08 0.56 0.80 0.83 0.80 0.07 0.06
BE3 0.10 3.01 4.51 4.88 4.64 0.14 0.08
t T g c t C C C A C A G G G C A G T A A A C G
Untreated 0.07 0.06 0.04 0.05 0.04 0.06
BE1 0.07 0.09 0.07 0.07 0.04 0.07
BE2 0.14 0.24 0.22 0.22 0.05 0.06
BE3 0.42 0.89 0.84 0.86 0.07 0.06
g c T G C C C C A C A G G G C A G c A A A G G
Untreated 0.07 0.06 0.06 0.11 0.03 0.07 0.14 0.09
BE1 0.08 0.06 0.06 0.10 0.03 0.05 0.10 0.08
BE2 0.09 0.13 0.15 0.17 0.09 0.05 0.12 0.09
BE3 0.09 0.80 0.86 0.87 0.75 0.07 0.11 0.09
g T g G C C C C A C A G G G C A G g A A T G G
Untreated 0.07 0.13 0.06 0.09 0.04 0.06
BE1 0.09 0.14 0.07 0.08 0.05 0.08
BE2 0.09 0.15 0.08 0.12 0.04 0.07
BE3 0.14 0.20 0.13 0.16 0.07 0.08
a T T G C C C C A C g G G G C A G T g A C G G
Untreated 0.12 0.19 0.73 0.40 0.16 0.20
BE1 0.16 0.20 0.76 0.47 0.19 0.25
BE2 0.14 0.16 0.77 0.51 0.17 0.28
BE3 0.36 0.42 0.95 0.73 0.20 0.21
a c T c t C C C A C A a G G C A G T A A G G G
Untreated 0.11 0.12 0.08 0.11 0.20 0.08 0.05 0.17
BE1 0.10 0.16 0.10 0.09 0.20 0.10 0.04 0.14
BE2 0.08 0.16 0.11 0.11 0.21 0.10 0.05 0.20
BE3 0.10 0.14 0.13 0.13 0.22 0.09 0.05 0.17
t c a G C C C C A C A G G G C A G T A A G G G
Untreated 0.03 0.07 0.07 0.09 0.05 0.05 0.08
BE1 0.14 0.09 0.09 0.11 0.06 0.06 0.14
BE2 0.27 0.09 0.22 0.25 0.19 0.05 0.09














Base editing efficiency, C to other bases (%)





(-) RGEN  RGEN BE3 Cas9
G A A C A C A A A G C A T A G A C T G C G G G
Untreated 0.04 0.05 0.04 0.16
BE1 0.65 10.29 0.04 0.18
BE2 7.32 14.69 0.03 0.17
BE3 11.74 33.30 0.07 0.18
G A A C A C A A t G C A T A G A t T G C C G G
Untreated 0.10 0.09 0.11 0.18
BE1 0.10 0.10 0.13 0.21
BE2 0.13 0.12 0.11 0.16
BE3 0.17 0.21 0.11 0.19
a A c t c C A A A G C A T A t A C T G C T G G
Untreated 0.09 0.09 0.34 0.25 0.09
BE1 0.08 0.07 0.37 0.24 0.08
BE2 0.09 0.07 0.38 0.19 0.08
BE3 0.09 0.07 0.38 0.24 0.07
HEK2
Base editing efficiency, C to other bases (%)









(-) RGEN  RGEN BE3 Cas9
G G C C C A G A C T G A G C A C G T G A T G G
Untreated 0.13 0.46 0.42 0.14 0.10 0.07
BE1 0.38 6.45 8.56 0.59 0.14 0.08
BE2 0.37 6.27 8.17 0.41 0.20 0.06
BE3 1.00 24.71 31.39 0.76 0.09 0.10
a G C t C A G A C T G A G C A a G T G A G G G
Untreated 0.12 0.04 0.04 0.14
BE1 0.12 0.04 0.07 0.13
BE2 0.13 0.05 0.08 0.17
BE3 0.13 0.09 0.05 0.13
G t g g C c c A g a G A G C A C G T G t G G G
Untreated 0.07 0.06 0.07 0.12 0.13
BE1 0.08 0.05 0.10 0.09 0.11
BE2 0.08 0.05 0.06 0.11 0.12
BE3 0.07 0.05 0.07 0.10 0.10
c a C C C A G A C T G A G C A C G T G c T G G
Untreated 0.08 0.07 0.07 0.05 0.01 0.14 0.06 0.04
BE1 0.09 0.06 0.08 0.06 0.03 0.13 0.04 0.04
BE2 0.09 0.07 0.07 0.06 0.02 0.10 0.05 0.05
BE3 0.08 0.05 0.08 0.06 0.02 0.13 0.05 0.05
c G g C C c a A C T G A G C A a G T G A T G G
Untreated 0.16 0.08 0.13 0.10 0.06 0.19
BE1 0.19 0.11 0.14 0.07 0.06 0.21
BE2 0.16 0.08 0.13 0.09 0.05 0.16
BE3 0.16 0.08 0.13 0.09 0.05 0.20
a G a C C A G A C T G A G C A a G a G A G G G
Untreated 0.08 0.10 0.06 0.20
BE1 0.09 0.12 0.06 0.19
BE2 0.08 0.12 0.06 0.19
BE3 0.10 0.11 0.05 0.16
G G C C a c t c a T G g c C A C a T a c T G G
Untreated 0.45 0.15 0.05 0.19 0.29 0.26 0.06
BE1 0.45 0.16 0.08 0.19 0.30 0.28 0.06
BE2 0.47 0.17 0.09 0.19 0.31 0.24 0.06
BE3 0.44 0.16 0.08 0.19 0.29 0.26 0.06
HEK3
Base editing efficiency, C to other bases (%)























(-) RGEN  RGEN BE3 Cas9
G G C A C T G C G G C T G G A G G T G G G G G
Untreated 0.16 0.11 0.20 0.07
BE1 0.17 6.18 0.25 0.07
BE2 0.65 10.35 0.84 0.06
BE3 2.34 41.18 0.80 0.07
G G C A C T G C t G C T G G g G G T G G T G G
Untreated 0.11 0.05 0.15 0.98
BE1 0.13 0.38 0.14 0.98
BE2 0.16 0.46 0.13 0.93
BE3 0.31 5.93 0.22 1.07
G G C A C T G C a - C T G G A G G T t G T G G
Untreated 0.08 0.05 0.07 0.05
BE1 0.10 0.22 0.09 0.05
BE2 0.11 0.22 0.07 0.05
BE3 0.09 0.39 0.08 0.03
G G C t C T G C G G C T G G A G G g G G T G G
Untreated 0.04 0.05 0.34 0.13
BE1 0.05 0.26 0.35 0.13
BE2 0.06 0.19 0.35 0.15
BE3 0.07 2.07 0.34 0.17
a G C A C T G C a G a T G G A G G a G G C G G
Untreated 0.08 0.07 0.11
BE1 0.09 0.11 0.11
BE2 0.09 0.07 0.10
BE3 0.10 0.52 0.20





t G C A C T G C G G C c G G A G G a G G T G G
Untreated 0.21 0.12 0.36 0.14 0.09
BE1 0.15 0.53 0.31 0.13 0.08
BE2 0.19 1.25 0.32 0.11 0.14
BE3 0.37 10.75 0.41 0.12 0.07
G G C A C T - g G G C T G a A G G T a G A G G
Untreated 0.09 0.05 0.08
BE1 0.07 0.15 0.05
BE2 0.08 0.17 0.07
BE3 0.07 0.18 0.06
G G C A C T G t G G C T G c A G G T G G A G G
Untreated 0.09 0.03 0.02 0.04
BE1 0.08 0.04 0.04 0.03
BE2 0.12 0.03 0.04 0.03
BE3 0.12 0.02 0.04 0.05
t G C t C T G C G G C a G G A G G a G G A G G
Untreated 0.08 0.17 0.06 0.06
BE1 0.07 0.17 0.06 0.05
BE2 0.08 0.18 0.07 0.07
BE3 0.08 0.19 0.07 0.07
a G C A C T G C a G C T G G g a G T G G A G G
Untreated 0.16 0.05 0.13 0.07
BE1 0.12 0.47 0.12 0.07
BE2 0.13 0.64 0.14 0.08
BE3 0.19 1.83 0.18 0.08





G G C A C T G g G G C T G G A G a c G G G G G
Untreated 0.13 0.15 0.13 0.23
BE1 0.12 0.14 0.11 0.18
BE2 0.10 0.13 0.09 0.15
BE3 0.11 0.12 0.12 0.18
a G g A C T G C G G C T G G g G G T G G T G G
Untreated 0.06 0.28 0.05
BE1 0.50 0.37 0.03
BE2 0.63 0.38 0.04
BE3 5.20 0.50 0.04
G G C A C T G C a a C T G G A a G T G a T G G
Untreated 0.11 0.06 0.12 0.03
BE1 0.10 0.08 0.07 0.02
BE2 0.08 0.08 0.08 0.02
BE3 0.10 0.26 0.09 0.03





G c C A C T G C a G C T a G A G G T G G A G G
Untreated 0.14 0.05 0.07 0.20 0.03
BE1 0.10 0.06 0.24 0.13 0.04
BE2 0.09 0.10 0.27 0.14 0.04
BE3 0.12 0.34 3.12 0.22 0.04
G c C A C T G C G a C T G G A G G a G G G G G
Untreated 0.14 0.07 0.06 60.77 0.04
BE1 0.10 0.05 0.08 61.73 0.03
BE2 0.12 0.03 0.05 60.63 0.05
BE3 0.10 0.08 0.12 60.98 0.04
G G C A C T G - G G C T G G A G G c G G G G G
Untreated 0.06 0.06 0.05 0.12
BE1 0.07 0.04 0.06 0.11
BE2 0.08 0.06 0.04 0.10
BE3 0.08 0.05 0.07 0.09
a G C t C T G C G G C a G G A G t T G G A G G
Untreated 0.24 0.02 0.20 0.12
BE1 0.21 0.03 0.20 0.08
BE2 0.21 0.02 0.17 0.08
BE3 0.23 0.02 0.22 0.11
HEK4
Base editing efficiency, C to other bases (%)










































(-) RGEN  RGEN BE3 Cas9
G T C A T C T T A G T C A T T A C C T G A G G
Untreated 0.07 0.06 0.03 0.07
BE1 2.90 0.08 0.03 0.07
BE2 3.89 0.62 0.05 0.08
BE3 31.12 3.45 0.16 0.08
RNF2
Base editing efficiency (%)







Table 3. Base editing efficiencies at Digenome-captured sites associated only 
with 3 different Cas9 nucleases. No substitutions were detectably induced by BE3 
at these Cas9-associated sites. On-target sequences (EXM1_On, HBB_On, and 







Table 4. Base editing efficiencies of 6 different BE3 deaminases at Digenome-
negative sites with ≤ 3 mismatches with respective on-target sequences. No 
substitutions were detectably induced by BE3 at these sites. On-target sequences 










Table 5. Off-target effect index (OTI)  
 






(By Kyoungmi Kim, Seuk-Min Ryu & Desik Kim in Institute for Basic Science) 
Figure 18. Digenome-seq to identify off-target site of BE3 in the mouse genome. 
(a) IGV image showing straight alignments of sequence reads at the Dmd on-target 
site. (b) Three sites, including the on-target site, were identified by Digenome 2.0. 
(c) No off-target substitutions were detectably induced at the two candidate sites 







4. Reducing BE3 off-target effects via modified sgRNAs  
To reduce BE3 off-target effects, I replaced standard GX19 (or gX19) 
sgRNAs (“g” and “G” represent, respectively, a mismatched and matched guanine) 
with truncated sgRNAs (Fu et al., 2014) (termed gX18 or gX17) or extended 
sgRNAs (Cho et al., 2014; Kim et al., 2015; Kim et al., 2016b) containing one or 
two extra guanines at the 5′ terminus (termed gX20 or ggX20) and measured on-
target and off-target base-editing frequencies in HEK293T cells (Figure 19, Figure 
20, and Table 6). Truncated sgRNAs reduced off-target effects at many sites but 
exacerbated them at sites with mismatches at the 5′ terminus (shown by asterisks in 
Figure 19b and Figure 20b). Extended sgRNAs reduced off-target effects at almost 
every site without sacrificing on-target effects. Notably, some extended sgRNAs 
were more active at on-target sites than GX19 (or gX19) sgRNAs (Table 6). Use of 
attenuated Cas9 variants (Kleinstiver et al., 2016; Rees et al., 2017; Slaymaker et 
al., 2016) or delivery of BE3 RNPs rather than plasmids (Kim et al., 2016a; Kim et 
al., 2014; Rees et al., 2017) may further improve the genome-wide specificity of 
base editing. Digenome-seq, at least in its current form, cannot be used for 
profiling specificities of BE1 and BE2, which are composed of dCas9 rather than 
nCas9. Note, however, that these dCas9-based deaminases are substantially less 
efficient than BE3. Because Digenome-seq is an in vitro method, it cannot identify 
DSB hotspots or uracil hotspots, if any, that may occur in cells independent of 
Cas9-sgRNA-DNA interactions. New methods may be developed in the future to 





Figure 19. Reducing BE3 off-target effects via modifying length of HBB-
targeting sgRNAs. (a) Sequences of sgRNAs at the 5′ terminus. (b) Base-editing 
frequencies at the HBB on- and off-target sites in HEK293T cells were measured 
by targeted deep sequencing. The heatmap represents relative specificities of 
modified sgRNAs, compared to that of gX19 sgRNA. The specificity ratio was 
calculated by dividing (on-target frequency of modified sgRNA/off-target 
frequency of modified sgRNA) by (on-target frequency of gX19 sgRNA/off-target 





Figure 20. Reducing BE3 off-target effects via modifying length of EMX1-
targeting sgRNAs. (a) Sequences of sgRNAs at the 5’ terminus. (b) Base editing 
efficiencies were measured at the EMX1 on- and off-target sites by targeted deep 
sequencing in HEK293T cells. The heatmap represents relative specificities of 
modified sgRNAs, compared to that of gX19 sgRNA. The specificity ratio was 
calculated by dividing (on-target frequency of modified sgRNA/off-target 
frequency of modified sgRNA) by (on-target frequency of gX19 sgRNA/off-target 
frequency of gX19 sgRNA). 
59 
 
Table 6. Analysis of BE3 off-target effects via modified sgRNAs.  
 
(Continued) 
G A G T C C G A G C A G A A G A A G A A G G G
Untreated 0.04 0.06 0.15
ggX20 49.01 46.36 0.10
gX20 54.78 50.04 0.14
GX19 49.17 45.06 0.10
gX18 48.68 37.61 0.09
GX17 48.71 37.70 0.14







G A a T C C a A G C A G A A G A A G A g A A G
Untreated 0.08 0.08 0.07
ggX20 0.40 0.36 0.05
gX20 0.80 0.75 0.07
GX19 0.84 0.81 0.07
gX18 0.22 0.23 0.08
GX17 0.16 0.17 0.06
a A G T C t G A G C A c A A G A A G A A T G G
Untreated 0.02 0.07 0.06
ggX20 0.03 0.06 0.06
gX20 0.03 0.07 0.05
GX19 0.13 0.07 0.05
gX18 0.02 0.07 0.05
GX17 0.02 0.08 0.04







G A G T C C t A G C A G g A G A A G A A G A G
Untreated 0.02 0.04 0.04
ggX20 0.34 0.35 0.05
gX20 1.69 1.71 0.05
GX19 2.43 2.40 0.04
gX18 0.02 0.02 0.05
GX17 0.02 0.04 0.04
G A G T C C a A G C A G t A G A g G A A G G G
Untreated 0.03 0.06 0.06
ggX20 0.03 0.06 0.08
gX20 0.04 0.08 0.08
GX19 0.07 0.10 0.07
gX18 0.03 0.05 0.09
GX17 0.03 0.05 0.08














G A G g C C G A G C A G A A G A A a g A C G G
Untreated 0.14 0.10 0.13
ggX20 0.26 0.21 0.12
gX20 0.44 0.39 0.19
GX19 3.45 3.70 0.17
gX18 0.17 0.10 0.15
GX17 0.18 0.09 0.16
a g t T C C a A G C A G A A G A A G c A T G G
Untreated 0.06 0.05 0.07 0.06
ggX20 0.27 0.28 0.07 0.07
gX20 0.74 0.70 0.07 0.08
GX19 0.74 0.62 0.06 0.07
gX18 0.06 0.05 0.07 0.06
GX17 0.07 0.06 0.07 0.07
G A G T C C a c a C A G A A G A A G A A A G A
Untreated 0.08 0.26 0.11 0.11
ggX20 0.07 0.21 0.12 0.11
gX20 0.09 0.23 0.09 0.11
GX19 0.17 0.33 0.17 0.10
gX18 0.07 0.25 0.10 0.13
GX17 0.08 0.23 0.11 0.11


















































G A a T C C a A G C A G g A G A A G A A G G A
Untreated 0.04 0.07 0.05
ggX20 0.09 0.15 0.04
gX20 0.54 0.60 0.08
GX19 0.14 0.18 0.05
gX18 0.04 0.07 0.05
GX17 0.01 0.07 0.06







G A G T C C c A G C A a A A G A A G A A A A G
Untreated 0.10 0.19 0.09 0.07
ggX20 0.10 0.16 0.10 0.07
gX20 0.19 0.24 0.13 0.05
GX19 0.11 0.20 0.07 0.07
gX18 0.12 0.24 0.09 0.06
GX17 0.12 0.20 0.07 0.06







a A G T C C a t G C A G A A G A g G A A G G G
Untreated 0.03 0.07 0.10
ggX20 0.05 0.07 0.09
gX20 0.03 0.08 0.12
GX19 0.24 0.30 0.12
gX18 0.03 0.08 0.10
GX17 0.05 0.07 0.09







G A G T C C c t - C A G g A G A A G A A A G G
Untreated 0.16 0.08 0.07 0.03
ggX20 0.12 0.07 0.06 0.04
gX20 0.15 0.11 0.08 0.04
GX19 0.24 0.17 0.16 0.06
gX18 0.12 0.09 0.07 0.04
GX17 0.14 0.08 0.06 0.02
a c G T C t G A G C A G A A G A A G A A T G G
Untreated 0.14 0.04 0.11
ggX20 0.14 0.16 0.13
gX20 0.15 0.20 0.16
GX19 0.15 0.62 0.12
gX18 0.22 1.24 0.12
GX17 0.13 4.49 0.11







G A G T C C t A a - A G A A G A A G c A G G G
Untreated 0.05 0.18 0.11
ggX20 0.06 0.20 0.16
gX20 0.07 0.19 0.12
GX19 0.05 0.22 0.12
gX18 0.07 0.19 0.15
GX17 0.04 0.18 0.12
c A G T C C a A a C A G A A G A g G A A T G G
Untreated 0.11 0.05 0.11 0.11
ggX20 0.11 0.08 0.12 0.09
gX20 0.10 0.05 0.10 0.10
GX19 0.11 0.07 0.13 0.11
gX18 0.13 0.05 0.14 0.13























G T C A T C T T A G T C A T T A C C T G A G G
Untreated  0.06 0.07 0.06 0.03 0.07
ggX20 22.35 29.23 3.10 0.10 0.08
gX20 20.82 28.93 3.23 0.10 0.09
GX19 19.23 31.12 3.45 0.16 0.08
gX18 9.19 19.16 1.61 0.07 0.08








G G A A T C C C T T C T G C A G C A C C T G G
Untreated 0.06 0.10 0.04 0.03 0.13 0.13 0.05 0.04
ggX20 9.20 8.19 7.94 4.25 0.12 0.12 0.06 0.04
gX20 8.12 7.31 6.89 3.01 0.13 0.12 0.05 0.03
GX19 10.26 9.44 9.28 4.12 0.18 0.12 0.05 0.04
GX18 9.74 8.81 8.16 3.14 0.15 0.14 0.06 0.02
gX17 3.36 2.80 2.77 1.14 0.12 0.12 0.05 0.04
t G A A T C C C a T C T c C A G C A C C A G G
Untreated 0.07 0.10 0.08 0.03 0.04 0.04 0.07 0.04 0.07
ggX20 0.06 0.11 0.07 0.03 0.03 0.05 0.11 0.03 0.06
gX20 0.09 0.10 0.09 0.04 0.02 0.05 0.09 0.03 0.09
GX19 0.16 0.16 0.18 0.06 0.05 0.07 0.09 0.03 0.07
GX18 0.80 0.79 0.79 0.25 0.13 0.08 0.10 0.03 0.06
gX17 0.08 0.10 0.09 0.02 0.03 0.06 0.09 0.02 0.07
G G A g T C C C T c C T a C A G C A C C A G G
Untreated 0.06 0.09 0.05 0.08 0.03 0.06 0.07 0.06 0.14
ggX20 0.06 0.08 0.04 0.07 0.04 0.06 0.05 0.07 0.15
gX20 0.10 0.13 0.08 0.10 0.05 0.07 0.06 0.07 0.15
GX19 0.20 0.23 0.18 0.16 0.06 0.08 0.06 0.07 0.18
GX18 0.05 0.09 0.05 0.08 0.03 0.05 0.06 0.08 0.17
gX17 0.05 0.08 0.04 0.11 0.05 0.06 0.07 0.09 0.15
G G A g T C C C T c C T a C A G C A C C A G G
Untreated 0.06 0.05 0.05 0.05 0.06 0.06 0.03 0.03 0.06
ggX20 0.05 0.05 0.05 0.04 0.04 0.07 0.04 0.03 0.04
gX20 0.08 0.07 0.06 0.06 0.08 0.06 0.02 0.02 0.06
GX19 0.11 0.09 0.12 0.05 0.06 0.07 0.04 0.04 0.04
GX18 0.07 0.07 0.06 0.05 0.06 0.07 0.04 0.03 0.07
gX17 0.06 0.05 0.04 0.06 0.04 0.07 0.03 0.02 0.06
G G A A T C C C T T C T a C A G C A t C C T G
Untreated 0.09 0.07 0.05 0.03 0.07 0.03 0.03
ggX20 0.07 0.07 0.04 0.04 0.06 0.03 0.02
gX20 0.07 0.05 0.06 0.04 0.05 0.04 0.03
GX19 0.10 0.07 0.05 0.03 0.07 0.03 0.02
GX18 0.08 0.06 0.06 0.03 0.07 0.04 0.03
gX17 0.09 0.05 0.05 0.05 0.08 0.04 0.02
G G A g T C C C T c C T G C A G C A C C T G A
Untreated 0.04 0.04 0.04 0.02 0.04 0.09 0.06 0.02 0.04
ggX20 0.03 0.04 0.04 0.02 0.04 0.12 0.05 0.03 0.06
gX20 0.05 0.06 0.05 0.03 0.06 0.11 0.07 0.06 0.04
GX19 0.13 0.09 0.09 0.05 0.06 0.12 0.06 0.05 0.03
GX18 0.06 0.05 0.04 0.03 0.04 0.08 0.07 0.04 0.05
gX17 0.05 0.05 0.04 0.04 0.05 0.14 0.05 0.05 0.04
G G A A c C C C g T C T G C A G C A C C A G G
Untreated 0.03 0.07 0.07 0.06 0.03 0.20 0.05 0.03 0.07
ggX20 0.27 0.29 0.28 0.32 0.10 0.21 0.05 0.02 0.07
gX20 1.46 1.50 1.49 1.48 0.80 0.20 0.04 0.04 0.06
GX19 1.06 1.07 1.07 1.02 0.71 0.22 0.07 0.03 0.07
GX18 0.04 0.07 0.05 0.09 0.01 0.17 0.04 0.04 0.06
gX17 0.04 0.06 0.04 0.09 0.01 0.17 0.05 0.03 0.06
G t c t c C C C T T C T G C A G C A C C A G G
Untreated 0.02 0.03 0.04 0.02 0.05 0.03 0.11 0.03 0.02 0.03
ggX20 0.02 0.01 0.03 0.05 0.05 0.01 0.08 0.02 0.02 0.04
gX20 0.01 0.02 0.04 0.04 0.04 0.02 0.08 0.02 0.03 0.03
GX19 0.02 0.02 0.04 0.04 0.08 0.03 0.10 0.03 0.02 0.03
GX18 0.04 0.09 0.09 0.10 0.13 0.05 0.10 0.04 0.03 0.03
gX17 0.04 0.09 0.11 0.11 0.13 0.07 0.11 0.05 0.02 0.04
a a A A T C C C T T C c G C A G C A C C T A G
Untreated 0.07 0.02 0.04 0.05 0.06 0.05 0.04 0.05 0.06
ggX20 0.08 0.03 0.04 0.03 0.06 0.06 0.05 0.05 0.04
gX20 0.09 0.03 0.04 0.04 0.05 0.05 0.04 0.06 0.04
GX19 0.10 0.04 0.05 0.05 0.06 0.06 0.04 0.05 0.03
GX18 0.10 0.06 0.07 0.06 0.05 0.07 0.03 0.06 0.04
gX17 0.06 0.06 0.06 0.05 0.06 0.04 0.03 0.05 0.06







G G A A T a t C T T C T G C A G C c C C A G G
Untreated 0.03 0.05 0.22 0.03 0.05 0.05 0.10
ggX20 0.03 0.05 0.23 0.02 0.06 0.04 0.09
gX20 0.03 0.03 0.23 0.03 0.05 0.05 0.10
GX19 0.04 0.03 0.21 0.02 0.06 0.05 0.09
GX18 0.03 0.04 0.20 0.02 0.04 0.05 0.07
gX17 0.04 0.05 0.24 0.02 0.06 0.06 0.08






a c c A T C C C T c C T G C A G C A C C A G G
Untreated 0.07 0.06 0.04 0.04 0.04 0.06 0.05 0.10 0.03 0.08 0.04
ggX20 0.13 0.07 0.05 0.04 0.05 0.05 0.02 0.08 0.04 0.03 0.06
gX20 0.10 0.08 0.04 0.04 0.04 0.06 0.04 0.09 0.04 0.07 0.04
GX19 0.13 0.08 0.15 0.15 0.14 0.13 0.09 0.10 0.04 0.06 0.04
GX18 0.14 0.12 1.03 0.99 0.94 0.40 0.14 0.09 0.04 0.05 0.05
gX17 0.15 0.15 2.04 1.96 1.94 0.75 0.26 0.10 0.04 0.06 0.04
t G A A T C C t a a C T G C A G C A C C A G G
Untreated 0.09 0.05 0.04 0.09 0.06 0.08 0.06
ggX20 0.10 0.05 0.04 0.08 0.07 0.11 0.07
gX20 0.08 0.05 0.05 0.12 0.07 0.09 0.06
GX19 0.10 0.08 0.03 0.11 0.07 0.10 0.07
GX18 0.46 0.42 0.04 0.13 0.05 0.08 0.06
gX17 0.10 0.05 0.03 0.11 0.06 0.09 0.07
c t c t g t C C T T C T G C A G C A C C T G G
Untreated 0.03 0.04 0.05 0.02 0.02 0.06 0.02 0.01 0.03
ggX20 0.03 0.03 0.04 0.03 0.02 0.07 0.01 0.02 0.04
gX20 0.04 0.03 0.06 0.03 0.02 0.05 0.02 0.03 0.04
GX19 0.03 0.02 0.07 0.03 0.02 0.05 0.03 0.02 0.04
GX18 0.03 0.04 0.05 0.03 0.03 0.05 0.02 0.02 0.02










































C T T G C C C C A C A G G G C A G T A A C G G
Untreated 0.05 0.08 0.03 0.05 0.04 0.04 0.08
ggX20 0.30 4.68 6.16 6.49 5.84 0.15 0.08
gX20 0.09 2.76 3.27 3.37 3.07 0.11 0.07
gX19 0.10 3.01 4.51 4.88 4.64 0.14 0.08
gX18 0.08 2.20 6.12 6.80 6.30 0.15 0.07
gX17 0.08 0.63 3.27 4.07 3.74 0.10 0.10
t T g c t C C C A C A G G G C A G T A A A C G
Untreated 0.07 0.06 0.04 0.05 0.04 0.06
ggX20 0.06 0.08 0.04 0.06 0.04 0.09
gX20 0.08 0.09 0.07 0.08 0.03 0.05
gX19 0.42 0.89 0.84 0.86 0.07 0.06
gX18 0.07 0.12 0.10 0.11 0.05 0.06
gX17 0.07 0.08 0.05 0.06 0.05 0.08
g c T G C C C C A C A G G G C A G c A A A G G
Untreated 0.07 0.06 0.06 0.11 0.03 0.07 0.14 0.09
ggX20 0.10 0.09 0.11 0.14 0.08 0.07 0.15 0.07
gX20 0.10 0.74 0.77 0.79 0.70 0.09 0.13 0.08
gX19 0.09 0.80 0.86 0.87 0.75 0.07 0.11 0.09
gX18 0.12 0.46 0.64 0.64 0.53 0.05 0.11 0.10
gX17 0.09 0.16 0.19 0.24 0.18 0.04 0.14 0.09
g T g G C C C C A C A G G G C A G g A A T G G
Untreated 0.07 0.13 0.06 0.09 0.04 0.06
ggX20 0.10 0.11 0.06 0.10 0.05 0.04
gX20 0.08 0.12 0.07 0.09 0.04 0.06
gX19 0.14 0.20 0.13 0.16 0.07 0.08
gX18 0.10 0.24 0.17 0.20 0.08 0.06
gX17 0.84 1.61 1.58 1.53 0.16 0.05
a T T G C C C C A C g G G G C A G T g A C G G
Untreated 0.12 0.19 0.73 0.40 0.16 0.20
ggX20 0.16 0.20 0.73 0.48 0.19 0.25
gX20 0.20 0.23 0.80 0.47 0.14 0.21
gX19 0.36 0.42 0.95 0.73 0.20 0.21
gX18 0.24 0.32 0.89 0.60 0.20 0.24
gX17 0.17 0.20 0.75 0.49 0.20 0.22
a c T c t C C C A C A a G G C A G T A A G G G
Untreated 0.11 0.12 0.11 0.20 0.08 0.05 0.17
ggX20 0.09 0.14 0.09 0.24 0.09 0.05 0.19
gX20 0.12 0.13 0.13 0.23 0.14 0.04 0.22
gX19 0.10 0.14 0.13 0.22 0.09 0.05 0.17
gX18 0.12 0.15 0.14 0.26 0.11 0.06 0.22
gX17 0.10 0.16 0.11 0.24 0.10 0.04 0.19
t c a G C C C C A C A G G G C A G T A A G G G
Untreated 0.03 0.07 0.07 0.09 0.05 0.05 0.08
ggX20 1.37 0.17 0.76 0.99 1.08 0.08 0.09
gX20 2.47 0.41 1.72 2.24 2.30 0.15 0.08
gX19 2.82 0.80 2.89 4.01 4.20 0.14 0.09
gX18 3.34 1.71 5.48 7.00 7.65 0.30 0.08
















G A A C A C A A A G C A T A G A C T G C G G G
Untreated 0.05 0.05 0.03 0.03 0.19
ggX20 30.30 47.30 0.03 0.14 0.15
gX20 36.76 44.99 0.08 0.13 0.16
GX19 11.89 34.66 0.05 0.27 0.15
gX18 2.02 45.27 0.02 0.03 0.19
gX17 2.77 30.94 0.02 0.03 0.18
G A A C A C A A t G C A T A G A t T G C C G G
Untreated  0.11 0.09 0.09 0.16
ggX20 0.12 0.09 0.14 0.18
gX20 0.17 0.14 0.13 0.19
GX19 0.19 0.22 0.12 0.18
gX18 0.12 0.10 0.11 0.20
gX17 0.11 0.09 0.13 0.20
a A c t c C A A A G C A T A t A C T G C T G G
Untreated  0.07 0.09 0.37 0.24 0.24
ggX20 0.09 0.08 0.39 0.24 0.30
gX20 0.08 0.08 0.38 0.25 0.28
GX19 0.08 0.08 0.38 0.24 0.27
gX18 0.08 0.08 0.39 0.24 0.30








G G C C C A G A C T G A G C A C G T G A T G G
Untreated  0.15 0.47 0.39 0.15 0.08 0.06
ggX20 6.89 25.21 26.19 0.61 0.07 0.05
gX20 6.36 32.68 37.05 1.76 0.06 0.11
GX19 0.93 25.39 32.09 0.75 0.09 0.13
GX18 0.95 14.23 21.59 1.68 0.09 0.10
gX17 0.14 0.65 0.85 0.40 0.10 0.06
a G C t C A G A C T G A G C A a G T G A G G G
Untreated  0.13 0.04 0.06 0.12
ggX20 0.13 0.05 0.05 0.14
gX20 0.12 0.04 0.04 0.15
GX19 0.14 0.09 0.04 0.17
GX18 0.14 0.04 0.06 0.13












G t g g C c c A g a G A G C A C G T G t G G G
Untreated  0.08 0.04 0.08 0.09 0.12
ggX20 0.07 0.04 0.09 0.10 0.12
gX20 0.08 0.06 0.08 0.10 0.09
GX19 0.07 0.05 0.08 0.10 0.18
GX18 0.08 0.05 0.10 0.10 0.11
gX17 0.07 0.05 0.09 0.08 0.12
c a C C C A G A C T G A G C A C G T G c T G G
Untreated  0.07 0.06 0.08 0.04 0.02 0.13 0.05 0.04
ggX20 0.09 0.06 0.09 0.06 0.03 0.11 0.06 0.04
gX20 0.08 0.07 0.07 0.06 0.03 0.12 0.06 0.06
GX19 0.07 0.06 0.10 0.06 0.02 0.11 0.06 0.05
GX18 0.08 0.07 0.10 0.05 0.02 0.12 0.04 0.04
gX17 0.08 0.07 0.08 0.05 0.01 0.10 0.07 0.05
c G g C C c a A C T G A G C A a G T G A T G G
Untreated  0.17 0.09 0.14 0.08 0.06 0.17
ggX20 0.17 0.08 0.15 0.09 0.04 0.19
gX20 0.16 0.08 0.13 0.09 0.03 0.18
GX19 0.16 0.10 0.13 0.09 0.05 0.20
GX18 0.19 0.08 0.15 0.09 0.05 0.18
gX17 0.18 0.07 0.14 0.07 0.06 0.19
a G a C C A G A C T G A G C A a G a G A G G G
Untreated  0.09 0.09 0.06 0.17
ggX20 0.08 0.11 0.05 0.19
gX20 0.09 0.11 0.04 0.19
GX19 0.08 0.11 0.05 0.18
GX18 0.10 0.11 0.03 0.14
gX17 0.11 0.11 0.06 0.15
G G C C a c t c a T G g c C A C a T a c T G G
Untreated  0.38 0.18 0.06 0.18 0.30 0.30 0.07 0.06
ggX20 0.42 0.15 0.07 0.20 0.28 0.27 0.07 0.05
gX20 0.39 0.14 0.08 0.15 0.28 0.21 0.08 0.06
GX19 0.44 0.15 0.07 0.17 0.28 0.26 0.08 0.06
GX18 0.45 0.14 0.07 0.16 0.25 0.26 0.06 0.05











G G C A C T G C G G C T G G A G G T G G G G G
Untreated  0.17 0.08 0.23 0.07
ggX20 1.97 48.84 1.50 0.08
gX20 1.20 44.02 1.39 0.06
GX19 1.38 41.26 0.50 0.10
GX18 0.27 39.88 1.43 0.07
gX17 0.23 5.72 1.10 0.35
G G C A C T G C t G C T G G g G G T G G T G G
Untreated  0.14 0.04 0.11 0.91
ggX20 0.17 0.39 0.13 0.93
gX20 0.21 1.86 0.15 1.11
GX19 0.27 6.55 0.25 0.99
GX18 0.16 0.11 0.14 0.90
gX17 0.15 0.06 0.10 0.93
G G C A C T G C a - C T G G A G G T t G T G G
Untreated  0.09 0.05 0.07 0.05
ggX20 0.08 0.10 0.09 0.04
gX20 0.10 0.26 0.09 0.06
GX19 0.09 0.27 0.09 0.04
GX18 0.08 0.05 0.06 0.05
gX17 0.08 0.04 0.07 0.05
G G C t C T G C G G C T G G A G G g G G T G G
Untreated  0.05 0.05 0.29 0.14
ggX20 0.13 2.87 0.34 0.13
gX20 0.11 2.94 0.38 0.14
GX19 0.10 2.53 0.35 0.15
GX18 0.04 0.13 0.30 0.12
gX17 0.05 0.05 0.29 0.13
a G C A C T G C a G a T G G A G G a G G C G G
Untreated  0.09 0.03 0.11
ggX20 0.11 0.03 0.09
gX20 0.08 0.07 0.14
GX19 0.15 0.58 0.17
GX18 0.08 0.03 0.09
gX17 0.06 0.03 0.10







t G C A C T G C G G C c G G A G G a G G T G G
Untreated  0.24 0.10 0.38 0.14 0.08
ggX20 0.18 0.38 0.29 0.13 0.06
gX20 0.19 1.64 0.36 0.14 0.09
GX19 0.43 9.74 0.32 0.13 0.08
GX18 1.01 11.33 0.56 0.11 0.08
gX17 0.18 0.16 0.26 0.13 0.08
G G C A C T - g G G C T G a A G G T a G A G G
Untreated  0.08 0.03 0.09
ggX20 0.18 0.64 0.05
gX20 0.18 0.62 0.05
GX19 0.07 0.16 0.06
GX18 0.08 0.03 0.08
























G G C A C T G t G G C T G c A G G T G G A G G
Untreated  0.11 0.03 0.04 0.03
ggX20 0.10 0.04 0.02 0.04
gX20 0.12 0.03 0.03 0.03
GX19 0.12 0.02 0.04 0.04
GX18 0.10 0.03 0.03 0.03
gX17 0.06 0.02 0.03 0.03
t G C t C T G C G G C a G G A G G a G G A G G
Untreated  0.08 0.18 0.07 0.07
ggX20 0.07 0.17 0.06 0.07
gX20 0.09 0.16 0.06 0.05
GX19 0.06 0.16 0.09 0.07
GX18 0.07 0.17 0.07 0.06
gX17 0.04 0.06 0.02 0.04
a G C A C T G C a G C T G G g a G T G G A G G
Untreated  0.16 0.05 0.15 0.08
ggX20 0.11 0.17 0.10 0.08
gX20 0.15 0.35 0.16 0.08
GX19 0.19 1.78 0.27 0.11
GX18 0.13 0.33 0.12 0.08
gX17 0.14 0.07 0.10 0.09
G G C A C T G a G G g T G G A G G T G G G G G






G G C A C T G g G G C T G G A G a c G G G G G
Untreated  0.12 0.13 0.12 0.21
ggX20 0.10 0.15 0.10 0.14
gX20 0.12 0.15 0.12 0.20
GX19 0.12 0.19 0.11 0.19
GX18 0.12 0.14 0.13 0.19
gX17 0.12 0.13 0.10 0.18
a G g A C T G C G G C T G G g G G T G G T G G
Untreated  0.05 0.29 0.03
ggX20 1.37 0.31 0.04
gX20 1.03 0.44 0.05
GX19 4.70 0.38 0.06
GX18 1.67 0.29 0.04
gX17 6.06 0.88 0.07
G G C A C T G C a a C T G G A a G T G a T G G
Untreated  0.11 0.06 0.11 0.02
ggX20 0.10 0.10 0.08 0.02
gX20 0.08 0.16 0.08 0.03
GX19 0.10 0.32 0.09 0.02
GX18 0.08 0.06 0.06 0.01
gX17 0.10 0.04 0.09 0.02
G G C A C T G g G G t T G G A G G T G G G G G






G c C A C T G C a G C T a G A G G T G G A G G
Untreated  0.11 0.05 0.05 0.16 0.04
ggX20 0.11 0.10 0.69 0.17 0.04
gX20 0.11 0.16 1.46 0.17 0.04
GX19 0.11 0.29 3.27 0.28 0.04
GX18 0.13 0.14 0.69 0.15 0.04
gX17 0.12 0.12 0.23 0.18 0.03
G c C A C T G C G a C T G G A G G a G G G G G
Untreated  0.16 0.06 0.06 61.49 0.05
ggX20 0.12 0.06 0.06 60.75 0.04
gX20 0.10 0.07 0.06 60.11 0.05
GX19 0.12 0.08 0.11 61.02 0.05
GX18 0.14 0.08 0.08 60.97 0.03
gX17 0.12 0.07 0.08 60.12 0.05
G G C A C T G - G G C T G G A G G c G G G G G
Untreated  0.03 0.06 0.05 0.08
ggX20 0.04 0.11 0.08 0.08
gX20 0.04 0.10 0.05 0.11
GX19 0.05 0.05 0.09 0.08
GX18 0.03 0.05 0.07 0.09
gX17 0.01 0.03 0.02 0.06
a G C t C T G C G G C a G G A G t T G G A G G
Untreated  0.22 0.03 0.22 0.10
ggX20 0.25 0.02 0.20 0.10
gX20 0.23 0.02 0.21 0.10
GX19 0.22 0.02 0.20 0.09
GX18 0.23 0.02 0.16 0.09



























5. Extended sgRNAs broaden the base editing window 
 
a. Base-editing efficiencies of cytosine base editor with 
extended sgRNAs. 
CBEs and ABEs are often limited by a narrow editing window of several 
nucleotide positions (typically, positions 12 to 17 (suboptimal) or positions 14 to 
17 (optimal)) upstream of a protospacer adjacent motif (PAM) sequence in the 
single-stranded, non-target DNA strand exposed for the deaminase reaction at a 
target protospacer site. To adjust this editing window, CBEs, namely, Base Editor 3 
(BE3) or Target-AID, have been combined with truncated sgRNAs in cultured 
human cells (Kim et al., 2017c) or with extended sgRNAs in E. coli (Banno et al., 
2018), respectively. Here, I tested a series of extended sgRNAs to achieve base 
editing at positions upstream of the current editing window in human cells.  
I transfected HEK293T cells with plasmids encoding BE3 and a 
conventional GX19 sgRNA (“G” or “g” indicates a matched or mismatched 
guanine, respectively, at the 5ʹ end, whereas “X19” indicates a 19-mer RNA 
sequence complementary with the protospacer DNA sequence) or eight extended 
sgRNAs with additional nucleotides in the 5ʹ terminus at 4 target sites (HBB, Site 
18, Site 19, HBB-E2). To measure substitution frequency, I performed targeted 
deep sequencing at each target (Figure 21). GX19 sgRNAs, mostly, were highly 
active at position 14 to 17, but some extended sgRNAs (ggX20, gX21, gX22 and 
gX23) were active at positions 18 to 22, upstream of the canonical base editing 
window. I focused on the relative efficiencies at each base position of (the 
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substitution frequency at each position normalized to the maximum substitution 
frequency), averaged over two tested sites which have cytosine within canonical 
base editing window (Figure 22). I noticed several extended sgRNAs could expend 








Figure 21. Base-editing efficiencies of cytosine base editor using extended 
sgRNAs. Extended sgRNAs with up to a 30-nucleotide spacer were tested in 
parallel with the conventional GX19 sgRNA at the HBB (a), Site 18 (b), Site 19 (c), 
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and HBB-E2 (d) target site in HEK293T cells. Substitution frequencies were 





Figure 22. Relative efficiencies of BE3 at each base position. (The substitution 
frequency at each position normalized to the maximum substitution frequency) 
were averaged over two tested sites (Site 18 and Site 19). The red line indicates the 
boundary of the conventional activity window. Data are presented as mean± s.e.m. 
(n = 3 biologically independent samples).  
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b. Base-editing efficiencies of adenine base editor with 
extended sgRNAs. 
To further characterization of base editing window using extended 
sgRNAs, I transfected HEK293T cells with plasmids encoding ABE7.10 and a 
conventional GX19 sgRNA targeted to the HEK2 site used in previous studies 
(Gaudelli et al., 2017; Kim et al., 2017a) or eight extended sgRNAs with additional 
nucleotides at the 5ʹ terminus and performed targeted deep sequencing to measure 
substitution frequencies (Figure 23). As expected, the GX19 sgRNA was highly 
efficient with an editing frequency of 73% at position 16 but was only slightly 
active (<0.6%) at positions 18 and 19 upstream of the canonical base editing 
window. In contrast, extended sgRNAs with a few additional nucleotides at the 5ʹ 
terminus (GX20, gX21, gX22, and gX23) showed base editing activity at positions 
18 and 19 with frequencies that ranged from 1.3% to 10%. sgRNAs with >23 base 
spacers were inactive at these positions and less active at positions even in the 
optimal editing window. Compared to the GX19 sgRNA, the GX20 sgRNA 
showed a 15-fold increase in the editing efficiency at positions outside of the 
canonical window (Figure 23b). Likewise, gX21, ggX20, gX22, and gX23 sgRNAs, 
targeted to four additional endogenous sites containing adenines at various 
positions, expanded the editing window, compared to gX19 and GX19 sgRNAs 
(Figure 24). 
Taken together, these results show that sgRNAs with a few extra 
nucleotides, targeted to five endogenous sites (Table 7) in the human genome, 
induced A-to-G conversions at positions upstream of the current editing window, 
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demonstrating that it is feasible to expand the window of adenine base editing in 
human cells (Figure 25 and Table 8). These extended sgRNAs broaden the editing 
window by 25% or 50%, from positions 14–17 (four nucleotides) to positions 14–







Figure 23. Base-editing efficiencies of adenine base editor using extended 
sgRNAs. (a) Extended sgRNAs with up to a 30-nucleotide spacer were tested in 
parallel with the conventional GX19 sgRNA at the HEK2 target site in HEK293T 
cells. Substitution frequencies were measured at each base position by targeted 
deep sequencing. (b) The left y axis indicates the percentage of alleles that contain 
a base substitution at a target adenine within two windows (positions 1–30 (gray 
bars) or 18–30 (black bars)). The relative base editing ratio (right y axis), indicated 
by the blue dots, was calculated by dividing the substitution frequency within the 
18–30 window by that within the 1–30 window. (c) Sequences of the most frequent 
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mutant alleles at the HEK2 site. Substituted nucleotides are shown in red. The PAM 





Figure 24. Activities of ABEs using extended sgRNAs in HEK293T cells. Base 
editing efficiencies of ABEs with extended sgRNAs at Site 18 (a), Site 19 (b), the 
HBB-E2 site (c), and the HBB-E3 site (d). (Left Y axis) Grey or black bars indicate 
the percentage of alleles that have a base-substitution mutation at the target adenine 
within two windows [positions 1-30 or 18-30 upstream from PAM], respectively. 
(Right Y axis) Blue dots indicate the relative base editing ratio, which was 
calculated by dividing the substitution allele frequency within the window of 
positions 18-30 by that within the window of positions 1-30. The PAM is shown in 




Table 7. ABE target sites in HEK293T cells.  
No. Sequence Chromosome Position Direction Reference 
HEK2 GAACACAAAGCATAGACTGCGGG chr5 87944780 - 87944799 + 3, 8 
Site18 ACACACACACTTAGAATCTGTGG chr1 184974900 - 184974919 + 3 
Site19 CACACACACTTAGAATCTGTGGG chr1 184974901 - 184974920 + 3 
HBB-E2 TCAGAAAGTGGTGGCTGGTGTGG chr11 5225630 - 5225649 -  







Figure 25. Relative efficiencies of ABE7.10 at each base position. (The 
substitution frequency at each position normalized to the maximum substitution 
frequency) were averaged over five tested sites (HEK2, Site 18, Site 19, HBB-E2, 
HBB-E3). The red line indicates the boundary of the conventional activity window. 
Data are presented as mean ± s.e.m. (n = 3 biologically independent samples). 




Table 8. Relative editing efficiencies at each base position at 5 endogenous sites 
in the human genome. The substitution frequency at each position was normalized 







6. Adenine base editing in mice using extended sgRNAs.  
Based on the results obtained from human cell data, extended sgRNA was 
used for generating mouse models. Himalayan mutation (Ch/Ch) in the Tyr gene in 
mice is caused by a naturally occurring A-to-G single-nucleotide variation, 
resulting in a histidine-to-arginine amino acid change (H420R) in the tyrosinase 
protein, an essential enzyme for pigmentation in animals. The Himalayan mouse is 
characterized by a partial albinism in adults but is indistinguishable from albinos at 
birth (Green, 1961; Kwon et al., 1989). The target adenine in the Tyr gene is 
located at position 18, one nucleotide upstream of the canonical base editing 
window (Figure 26a), providing us with the right conditions for a proof-of-
principle experiment in animals with extended sgRNAs. Each of three sgRNAs 
(gX19, GX20, and GX21) with ABE7.10 mRNA were delivered into mouse 
embryos by microinjection and genomic DNA isolated from the resulting 
blastocysts were analyzed. The three sgRNAs were almost equally efficient with 
average editing efficiencies of 78%, 95%, and 78%, respectively (Figure 26b). The 
Himalayan allele, however, was detected in just one out of eight embryos (13%) 
with a frequency of 10%, when the gX19 sgRNA was injected (Figure 26c,d). Thus, 
the overall frequency of the Himalayan allele obtained with the gX19 sgRNA was 
1.3%. Notably, the mutant allele was created in 5 of 16 (31%) and 8 of 12 (67%) 
embryos with frequencies of up to 47% and 94%, respectively, when GX20 and 
GX21 sgRNAs, respectively, were used. As a result, the overall frequencies of the 
Himalayan allele obtained with these extended sgRNAs were 8.5% (GX20) and 20% 
(GX21) (Figure 27a). 
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I chose the GX21 sgRNA for further experiments and transplanted the 
resulting ABE-injected embryos into surrogate mothers to obtain several offspring 
carrying point mutations at the Tyr target site. Seven out of nine F0 mice (78%) 
harbored base substitutions, with frequencies that ranged from 12% to 100% 
(Figure 27b and Figure 28). One F0 mouse showed an albino phenotype in the eye 
even at birth (Figure 27c). Targeted amplicon sequencing revealed that this mouse 
was not genetically mosaic at the target site, carrying two Himalayan alleles. All of 
the other mutant mice were mosaic with at least three alleles or two non-
Himalayan-mutant alleles. Altogether, base editing in 43 out of 45 (96%) embryos 
or pups with frequencies were ranged from 18% to 100% (Figure 26d and Figure 
27d). I also verified the germline transmission of mutant alleles to F1 offspring 
(Figure 29).  
To assess off-target effects, I first used Cas-OFFinder (Bae et al., 2014) to 
identify potential off-target sites with up to 3-nucleotide mismatches in the mouse 
genome (Table 9). No off-target mutations were detectably induced at these sites in 
three Tyr mutant mice (Figure 30). Furthermore, to assess off-target effects in the 
Tyr mutant mouse (Tyr #4) carrying two Himalayan alleles, WGSs were carried. No 
off-target base editing was observed at potential off-target sites, identified 207,848 
candidate sites that differed from the on-target site by up to seven mismatches, or 
identified 1,030,669 candidate sites that differed from the on-target site by up to 
five mismatches with an RNA or DNA bulge (Table 10). As a result, there were no 
off-target effects confirmed by deep-sequencing and WGS, revealing the high 





(By Seuk-Min Ryu & Kyoungmi Kim in Institute for Basic Science) 
Figure 26. Adenine editing efficiencies in mouse embryos. (a) The target 
sequence at the Tyrosinase (Tyr) locus. The PAM sequence is shown in blue. The 
sgRNA target sequence is underlined. The targeted adenine in the wild-type 
sequence and the expected change in the sequence are shown in green and red, 
respectively. (b) Point mutation efficiencies associated with sgRNAs of different 
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lengths (gX19, GX20, and GX21). Data are presented as mean ± s.e.m. (n = 8, 16 
and 12 blastocysts, respectively). (c) Frequencies of blastocysts that carry the 
H420R mutation (Himalayan allele). (d) Alignments of mutant sequences from 
blastocysts after microinjection of ABE mRNA and Tyr-targeting sgRNAs of 
different lengths. The PAM and substitutions are shown in blue and red, 
respectively. The numbers in the column on the right indicate the frequency of each 







(By Seuk-Min Ryu & Kyoungmi Kim in Institute for Basic Science) 
Figure 27. Frequencies of ABE-induced substitutions in the Tyr gene in mouse 
embryos and newborn pups. (a) Substitution frequencies at each position in the 
targeted locus. Results obtained with gX19, GX20, and GX21 sgRNAs are shown 
in yellow, green, and blue, respectively. Data are presented as mean ± s.e.m. (n = 8, 
16, and 12 blastocysts, respectively). (b) Alignments of mutant sequences from 
newborn pups. The mutant sequences and the PAM site are shown in red and blue, 
respectively. The targeted position is shown in green. (c) Tyr mutant F0 pups that 
developed after microinjection of the ABE mRNA; one pup exhibited an albino 
phenotype in its eyes (Tyr #4, black arrow) and coat color. (d) Summary of adenine 




(By Seuk-Min Ryu & Kyoungmi Kim in Institute for Basic Science) 
Figure 28. Tyr mutations in newborn pups. Alignments of mutant sequences 
from newborn pups. The altered nucleotides and the PAM site are shown in red and 







(By Seuk-Min Ryu & Kyoungmi Kim in Institute for Basic Science) 
Figure 29. Germline transmission of Tyr mutant alleles. Germline transmission 
of mutant alleles to F1 pups (101, 201-206, and 301-303) from F0 Tyr mutant mice 
(Tyr #1, Tyr #2 and Tyr #3) was confirmed using targeted deep sequencing. The 
PAM site and altered nucleotides are shown in blue and red, respectively. The 




Table 9. Potential off-target sites in the mouse genome. Potential off-target 
sites were identified using Cas-OFFinder.  
 





(By Seuk-Min Ryu & Kyoungmi Kim in Institute for Basic Science) 
Figure 30. No off-target mutations at candidate sites in Tyr mutant mice. 
Potential off-target sites with up to 3 mismatches, relative to the wild-type 
sequence, were identified using Cas-OFFinder. Substitution frequencies at these 
potential off-target sites were measured using targeted deep sequencing. PAM 
sequences and mismatched nucleotides are shown in blue and red, respectively. 




Table 10. Whole genome sequencing to assess off-target effects in the Tyr 
mutant mouse. Genomes from the Tyr mutant mouse (Tyr #4) and a wild-type 
(WT) control mouse were sequenced using Illumina HiSeq X10. Unique single 
nucleotide variants (SNVs) in Tyr #4 by trimming out those in the WT control 
using the program ‘Strelka’ with the default ‘eland’ option. None of these SNVs 
other than the variations at the on-target site were found at potential off-target sites, 
identified using Cas-OFFinder, with up to 7 mismatches (207,848 sites) or with up 
to 5 mismatches and a DNA or RNA bulge (1,030,669 sites). 
 





The newly developed base editors are powerful tools for introducing point 
mutations at the desired locus. I tested various types of base editors, such as BE1, 
BE2, BE3, and ABE7.10 in PCR products, genomic DNA, mammalian cell lines, 
and mouse. Both in vitro and in vivo experiments were performed with high 
efficiency. Despite the successful base-editing, off-target effects were one major 
concern, especially for therapeutic use. Like all CRISPR-meditated genome-editing 
technologies, the base editors use binding activities of CRISPR-system, so they 
have the potential to operate on off-target DNA at the genomic locus. However, the 
genome-wide target specificities of CRISPR RNA-guided base editors remain 
unknown, owing to a lack of appropriate methods. 
To develop a new method for assessing genome-wide specificities of 
CRISPR RNA-guided base editing, I modified Digenome-seq, in vitro Cas9-
digested whole-genome sequencing. Genomic DNA was treated with the base 
editor and USER, uracil-specific excision reagents, in vitro to produce DNA 
double-strand breaks at uracil-containing sites. Off-target sites were then 
computationally identified from whole genome sequencing data. Testing seven 
different single guide RNAs (sgRNAs), I found that the rAPOBEC1–nCas9 base 
editor was highly specific, inducing cytosine-to-uracil conversions at only 18 ± 9 
sites in the human genome for each sgRNA. Digenome-seq was sensitive enough 
to capture off-target sites with a substitution frequency of 0.1%. Notably, off-target 
sites of the base editors were often different from those of Cas9 alone, calling for 
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the independent assessment of their genome-wide specificities.   
To minimize off-target effects, I changed the length of conventional 
sgRNAs which has 20nt complementarity to the target DNA. First, truncated 
sgRNAs, termed gX18 or gX17, were tested. Generally, substitutions events at off-
target sites were decreased using truncated sgRNAs, but rather its efficiency 
increased in some off-target sites that have mismatches at 5’ end. Second, I used 
sgRNAs with additional guanine bases at the 5’end, termed gX20 or ggX20. These 
extended sgRNAs discriminated on-target sites from off-target sites without 
sacrificing activities in on-target sites. Recently, several groups independently 
reported strategies for avoiding off-target effects, by use of Cas9 variants having 
higher specificity (Hu et al., 2018; Kleinstiver et al., 2016; Slaymaker et al., 2016), 
or delivery as ribonucleoprotein (Kim et al., 2014; Ramakrishna et al., 2014; Zuris 
et al., 2015) to minimize the operating time. Schemes to reduce the off-target of 
CRISPR nucleases were applicable to CRISPR deaminases, which is expected to 
be further improved regarding specificity. 
CBEs and ABEs enabled to produce or eliminate single-nucleotide 
variations, a major source of pathogenic genetic diseases. Nevertheless, the activity 
window of base editors sometimes makes it impossible to change the bases at 
desired positions. Base editing windows of CBEs were known as positions 12 to 17 
for BE1/2/3 (Komor et al., 2016) and positions 17 to 19 (optimal) or 13 to 19 
(suboptimal) for Target-AIDs (Nishida et al., 2016), counting the position of a 
protospacer from the PAM. Base editing window of ABEs was positions 14 to 17 
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(optimal) or 12 to 17 (suboptimal) of upstream of PAM sequence at a target 
protospacer site (Gaudelli et al., 2017). I increased the length of sgRNA by 
extension the length of protospacer sequence up to 30nt, termed gX30~gX21, or 
with additional guanine bases at the 5’ end, termed gX20 or ggX20.  
BE3s using extended sgRNAs, like ggX20, gX21, gX22, and gX23, 
showed their activities at positions 13 to 22 from the PAM, beyond the base editing 
windows of Target-AIDs. Similarly, ABE7.10 with gX21, ggX20, gX22, and gX23 
sgRNAs broadened the base editing window to positions 14 to 19. As In vitro 
experiments in HEK293 cells, ABE induced base editing in vivo in mouse at PAM-
distal region compared to the conventional base editing window. Extended sgRNAs 
combined with engineered S. pyogenes Cas9 variants such as xCas9 and Cas9-NG 
having NG PAM (Hu et al., 2018; Nishimasu et al., 2018) or VQR-Cas9 having 
NGA PAM (Kim et al., 2017c), and either other types of CRISPR such as Cpf1 
having TTTV PAM (Li et al., 2018), may further expand the targetable range of 
base editing. 
In summary, results obtained using mismatched sgRNAs, Digenome-seq, 
and targeted deep sequencing, showed that BE3 deaminases were highly specific, 
catalyzing C-to-U conversions in vitro and base editing in human cells at a limited 
number of sites in the human genome. I found that BE3 and Cas9 off-target sites do 
not always coincide, justifying independent assessments of each tool. And I 
demonstrated that ABEs could be used to make disease models with single-
nucleotide substitutions in mice. Also, the extended sgRNAs with a few additional 
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nucleotides at the 5ʹ end could expand the window of base editing in vitro and in 
vivo. I expect that these results and methods will accelerate the broad use of RNA-
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지난 몇 년 동안, CRISPR-Cas9 기술은 유전체 교정 연구뿐만 
아니라 원하는 위치에 특정 기능을 도입할 수 있는 방법으로 개발되어 
왔다. Cas9 유전자 가위에 의해 DNA 이중가닥 절단이 일어나고 유사한 
염기 서열을 갖는 외부 DNA가 존재하면, 세포 내 DNA 이중가닥 절단 
복구 메커니즘 중 하나인 상동 재조합 방법을 통해 점 돌연변이를 유도
할 수 있다. 그러나 상동 재조합 기작과 경쟁적으로 작동하는 비상동성 
말단 접합이 우세하기 때문에 세포 내에서 점 돌연변이를 유도할 수 있
는 상동 재조합의 효율은 상대적으로 낮고, 세포 유형에 따라 상동 재조
합의 효율이 다르게 나타난다.  
이러한 제한점을 넘어 최근에 개발된 CRISPR 염기교정 유전자 
가위는 염기 치환을 할 수 있는 새로운 방법을 제시하였다. 염기교정 유
전자 가위는 DNA 이중가닥 절단 활성에 결함이 있는 Sterptococcus 
pyogenes Cas9 (dCas9 또는 nCas9) 과 단일 염기를 바꿀 수 있는 
deaminase를 연결하여 만든 재조합 단백질이다. 염기교정 유전자 가위
에는 시토신을 티민으로 치환 가능한 시토신 염기교정 유전자 가위와 아
데닌을 구아닌으로 바꿀 수 있는 아데닌 염기교정 유전자 가위가 있다. 
특정 위치에 이중가닥 절단을 일으켜 변이를 유도하는 유전자 가위들과
는 다르게, 염기교정 유전자 가위는 DNA 이중가닥 절단 복구 메커니즘
에 의존하지 않고 원하는 염기를 바꿀 수 있다. 이러한 큰 장점에도 불
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구하고, 아직까지 염기교정 유전자 가위의 게놈 전반에 걸친 표적 특이
성에 대해서는 밝혀진 바가 없었다. 
이 연구에서는 보고된 DNA 이중가닥 절단이 일어난 곳을 확인
할 수 있는 방법 중 하나인 Digenome-seq을 변형하여 시토신 염기교
정 유전자 가위의 특이성을 확인하고자 하였다. 인위적으로 이중가닥 절
단을 유도하기 위하여 DNA에 시토신 염기교정 유전자 가위와 함께 우
라실을 특이적으로 자를 수 있는 효소들을 함께 처리하였다. 그 후, 게
놈 전반에서 나타나는 시토신 염기교정 유전자 가위의 비표적 효과들을 
확인하였고, 기존의 유전자 가위와 비교하여 시토신 염기교정 유전자 가
위가 훨씬 정교하다는 것을 알 수 있었다. 관찰된 비표적 효과를 줄이기 
위하여 가이드 RNA의 길이를 줄이거나 말단에 구아닌 염기를 추가하여 
길이를 늘려보았고, 변형된 가이드 RNA를 이용하면 전반적으로 특이성
이 향상됨을 확인하였다. 나아가 길이를 연장시킨 가이드 RNA를 사용
한 시토신 또는 아데닌 염기교정 유전자 가위는 기존 염기 작동 범위보
다 PAM으로부터 먼 부위에서도 작동할 수 있었다. 결과적으로 염기교
정 유전자 가위의 변형된 가이드 RNA를 이용하면 염기교정 유전자가위
의 정확성과 범용성을 개선할 수 있음을 입증하였다. 
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